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Datum der Disputation: Identifikation und Charakterisierung intrazellulärer 
Interaktionspartner des metabotropen Glutamatrezeptors mGluR8 
 
Zusammenfassung 
 
Glutamat  ist  einer  der  wichtigsten  exzitatorischen  Neurotransmitter  im  Gehirn. 
Glutamatrezeptoren  werden  in  zwei  verschiedene  Klassen  unterteilt:    ionotrope 
(iGluRs) und metabotrope Glutamatrezeptoren (mGluRs). Die iGluRs bilden einen 
Ionenkanal und sind postsynaptisch lokalisiert. Dagegen zählen mGluRs zur Familie 
der  G-Protein  gekoppelten  Rezeptoren  (GPCRs)  und  sind  sowohl  post-  als  auch 
präsynaptisch  zu  finden.  mGluRs  spielen  eine  Rolle  bei  der  Regulation  der 
Transmitterfreisetzung,  der  Kurz-  und  Langzeit-Modulation  von  synaptischer 
Transmission,  der  neuronalen  Entwicklung  und  der  synaptischen  Plastizität. 
Mittlerweile sind acht verschiedene mGluR-Isoformen in Säugerzellen identifiziert 
worden, die in drei Gruppen eingeteilt werden. Gruppe I Rezeptoren (mGluR1 und 5) 
sind  hauptsächlich  postsynaptisch  lokalisiert  und  aktivieren  die  Phospholiapse  C. 
Gruppe II (mGluR2 und 3) und Gruppe III (mGluR4, 6, 7 und 8) Rezeptoren sind 
hauptsächlich präsynaptisch zu finden und inhibieren die Adenylat-Zyklase.  
Es  exisitieren  drei  mGluR8-Isoformen  (a,  b  und  c),  wobei  sich  mGluR8a  von 
mGluR8b nur in den letzten 16 Aminosäuren unterscheidet. Bei mGluR8c scheint es 
sich um eine sekretierte Isoform zu handeln, die nur aus der N-terminalen Region des 
gesamten  Proteins  besteht.  Obwohl  bereits  pharmakologische  Studien  an  mGluR8 
durchgeführt wurden und auch eine mGluR8-“Knockout”-Maus generiert wurde, ist 
nur  wenig  über  die  Funktion  dieses  Rezeptors  bekannt.  Deshalb  wurden  in  der 
vorliegenden  Arbeit  “Hefe-Zwei-Hybrid”-Untersuchungen  mittels  des  “DupLexA 
yeast  two-hybrid”-Systems  durchgeführt.  Dabei  dienten  die  C-terminale  Domänen 
(CTDs) von mGluR8a und mGluR8b als “Köder” zum Durchsuchen einer adaptierten 
Rattenhirn-cDNA-Bibliothek,  die  verschiedene  offene  Leseraster  beinhaltet.  In 
Hefezellen,  in  denen  es  zu  einer  Interaktion  zwischen  “Köder”-  und  einem  der 
“Beute”-Proteine kommt, wird die Expression von speziellen Reportergenen (Leu und 
LacZ) aktiviert und somit eine Selektion der positiven Klone ermöglicht. Es wurden 
für  mGluR8a  6x10
8  Hefezellen  und  für  mGluR8b  8,4x10
4  Hefzellen  analysiert, 
wovon 1385 bzw. 934 Klone Leucin-auxotroph waren und LacZ exprimierten. Mittels DNA-Sequenzierung  konnten  ca.  30  Proteine  als  potenzielle  Interaktionspartner 
identifiziert werden, die in drei Klassen eingeteilt wurden. Die erste Gruppe beinhaltet 
Sumoylierungsproteine.  Bei  der  Sumoylierung  wird  das  SUMO-Protein  (Small 
ubiquitin related modifier) kovalent an einen Lysinrest des Subtrates gebunden. Für 
den Sumoylierungsprozess sind drei Enzyme notwendig: das aktivierende Enzym E1, 
das  konjugierende  Enzym  E2  und  die Ligase  E3.  Durch  die  “Hefe-zwei-Hybrid”-
Analyse wurden fünf Proteine identifiziert, die mit der Sumoylierung in Verbindung 
stehen:  Pias1,  Piasxβ  und  ube2a,  die  während  der  Untersuchungen  als  häufigste 
Interaktionspartner  auftraten, und SUMO-1 und Piasγ, die nur als Interaktoren für 
mGluR8b identifiziert wurden. Bei SUMO-1 handelt es sich um E1-, bei ube2 um E2- 
und bei Pias1, Piasxβ und Piasγ um E3-Enzyme. Die zweite Klasse der potenziellen 
Interaktionspartner  umfasst  apoptotische  Proteine:  Hipk3  und  Fas-related  Protein. 
Alle zusätzlich identifizierten Kandidaten sind in Gruppe 3 zusammengefasst. In der 
vorliegenden  Arbeit  wurde  die  Interaktion  mit  Sumoylierungs-Proteinen  näher 
analysiert.  
Um Interaktionen zwischen den identifizierten Proteinen und mGluR8 zu bestätigen, 
wurde ein Hefe-Paarungs-Experiment durchgeführt. Hierzu wurden haploide RFY206 
Zellen (MATa), die das „Köder“-Protein exprimierten, wurden mit haploiden EGY48 
Zellen (MATα), die das „Beute“-und ein Reporterprotein koexprimierten, verwendet. 
Kultiviert man solche Hefezelltypen entgegengesetzten „Matingtyps“ miteinander, so 
können sie miteinander fusionieren und dadurch eine diploide Zelle bilden. Da in 
diesem  experimentellen  Ansatz  alle  Zellen,  die  die  fünf  Sumoylierungsproteine 
exprimierten, Leucin-auxotroph waren und LacZ-Expression aufwiesen, wurden diese 
Proteine  als  Interaktionspartner  sowohl  für    mGluR8a  als  auch  für  mGluR8b 
eingestuft (siehe Tabelle 7). Mittels dieses Ansatzes konnten Piasγ und SUMO-1, die 
mit der „Hefe-Zwei-Hybrid“-Untersuchung nur als potenzielle Interaktoren des C-
Terminus  von  mGluR8b  identifiziert  worden  waren,  auch  als  mögliche 
Bindungspartner des C-Terminus von mGluR8a nachgewiesen werden. 
Um  die  Ergebnisse  der  „Hefe-Zwei-Hybrid“-Analyse  zu  bestätigen,  wurden 
GST(Glutathion-S-Transferase)-Pulldown-Experimente  angewandt.  Dazu  wurden 
GST-Fusionsproteine des C-Terminus von mGluR8a (GST-mGluR8a-C) und des C-
Terminus von mGluR8b (GST-mGluR8b-C) in E. coli exprimiert und anschließend an 
einer Glutathion-Sepharose-Matrix, an die GST spezifisch bindet, immobilisiert. Die potenziellen  Interaktionspartner  ube2,  Pias1  und  Piasγ  wurden  dagegen  als 
MBP(myelin  basic  protein)-Fusionsproteine  in  Bakterien  exprimiert.  Nachdem  die 
Interaktoren mit den immobilisierten GST-C-Termini inkubiert worden waren, wurde 
die  Sepharose-Matrix  gewaschen,  um  nichtgebundene  Moleküle  zu  entfernen,  und 
anschließend  mit  SDS-Probenpuffer  versetzt,  um  die  gebundenen  Proteine  zu 
eluieren. Danach wurden die erhaltenen Proben mittels SDS-PAGE aufgetrennt und 
schließlich  durch  ein  Western-Blotting  analysiert,  wobei  ein  Antikörper,  der 
spezifisch MBP erkennt, verwendet wurde. Die Ergebnisse zeigten, dass MBP-Pias1 
mit GST-mGluR8b-C und, in vergleichsweise geringerem Maße, mit GST-mGluR8a-
C aufgereinigt werden konnte. Eine deutlich schwächere Interaktion konnte zwischen 
dem MBP-Fusionsprotein des C-Terminus von Piasγ und den beiden C-Termini der 
mGluR8-Isoformen  detektiert  werden.  Dagegen  konnte  für  MBP-ube2a  keine 
Bindung  an  die  beiden  C-Termini  gezeigt  werden.  Als  Negativkontrolle  wurde 
immobilisiertes GST mit MBP und auch mit den MBP-Fusionsproteinen inkubiert, 
wobei in allen Fällen keine Interaktion festgestellt werden konnte.   
Zusätzlich wurden die potenziellen Interaktionspartner (Pias1, ube2a und SUMO-1) 
als GFP („green fluorescent protein“)-, YFP („yellow fluorescent protein“)- und CFP 
(„cyan fluorescent protein“)-Fusionsproteine in Säugerzellen (HEK 293) exprimiert. 
Diese  wurden  anschließend  ebenfalls  in  einem  GST-Pulldown-Experiment  mit 
immobilisertem GST-mGluR8a-C bzw. GST-mGluR8b-C inkubiert. Dabei konnte die 
starke Interaktion zwischen GST-mGluR8a-C und Pias1 bestätigt werden, wogegen 
nur eine sehr schwache Bindung von ube2a und SUMO1 an die GST-Fusionsproteine 
detektiert  werden  konnte.  Diese  Ergebnisse  zeigen,  dass  von  den  untersuchten 
möglichen Interaktoren Pias1 die stärkste Bindung an mGluR8  aufweist.  
Im Anschluss an diese Untersuchungen wurde überprüft, ob Pias1 auch an weitere 
präsynaptisch lokalisierte mGluRs der Gruppen II und III binden kann, oder ob diese 
Interaktion spezifisch für mGluR8 ist. Hierzu wurden binäre „Hefe-Zwei-Hybrid“-
Analysen durchgeführt. Die so erhaltenen Daten weisen darauf hin, dass zwar auch 
eine Affinität für andere Gruppe III mGluRs besteht, die Interaktion mit mGluR8 
jedoch deutlich stärker ist. Dagegen konnte keine Bindung von Pias1 an die Gruppe II 
mGluRs mGluR2-C und mGluR3-C aufgezeigt werden. Zur Bestätigung dieser Daten 
erfolgten anschliessend GST-Pulldown-Analysen mit GFP-Pias, das in Säugerzellen 
exprimiert  worden  war,  und  den  GST-Fusionsproteinen  der  C-Termini  der  bereits genannten  mGluRs.  Als  Negativkontrollen  wurden  immobilisiertes  GST  mit  GFP-
Pias1 bzw. GFP mit GST-mGluR7a-C inkubiert, wobei keine Interaktionen erhalten 
wurden. In diesen Pulldown-Experimenten konnte für alle Gruppe III mGluRs eine 
Bindung an Pias1 nachgewiesen werden. Aus diesen Ergebnissen lässt sich schließen, 
dass alle C-Termini der Gruppe III mGluRs mit Pias1 interagieren können.  
Um die Domänen von mGluR7a-C und mGluR8a-C, die mit Pias1 interagieren, zu 
identifizieren,  wurden  je  zwei  Fragmente  der  C-terminalen  Domänen  der  beiden 
Rezeptoren  als  GST-Fusionsproteine  exprimiert  und  in  einem  GTS-Pulldown-
Experiment mit CFP-Pias1 inkubiert. Starke Interaktion konnten zwischen Pias1 und 
den Trunkationen mGluR7a-N38 bzw. mGluR8a-C44 nachgewiesen werden. Diese 
beiden Domänen überlappen in 17 Aminosäuren, wobei nur die sechs letzten, die das 
Sumoylierungsmotif enthalten, identisch sind. Diese Ergebnisse weisen darauf hin, 
dass diese Aminosäurereste wichtig für die Bindung der Gruppe III mGluRs an Pias1 
sind.  
Im Folgenden wurde untersucht, ob mGluRa-C in vivo  sumoyliert wird. Da bei der 
Sumoylierung  SUMO-1  kovalent  an  die  Aminogruppe  eines  Lysinrestes  des 
Substratproteins  gebunden  wird,  erfolgt  eine  detektierbare  Größenveränderung 
desselben.  Für  die  in  vivo-Sumoylierung-Analyse  wurden  GFP-mGluR8a-c,  YFP-
ube2a  und  CFP-SUMO-1  in  HEK  293  Zellen  koexprimiert.  Der  Zellextrakt  der 
transfizierten Zellen wurde durch SDS-PAGE aufgetrennt und anschließend mittels 
Western Blotting mit einem Antikörper, der spezifisch den C-Terminus von mGluR8 
erkennt, analysiert. Dabei wurde für ca. 1% des exprimierten mGluR8a-C-Proteins 
eine Erhöhung des Molekulargewichtes um ungefähr 40 kDa gefunden, was genau der 
Addition  eines  GFP-SUMO-1  Moleküls  entspricht.  Zusätzlich  konnte  eine 
Proteinbande des gleichen Molekulargewichts mit einem Antikörper, der spezifisch 
SUMO-1 erkennt, nachgewiesen werden, was bestätigt, dass es sich bei dieser Bande 
tatsächlich um das sumoylierte mGluR8a-C-Protein handelte. Um den Lysinrest (K) 
in mGluR8 zu identifizieren, an dem die Sumoylierung erfolgt, wurden drei Lysine, 
die in mGluR8a und mGluR8b konserviert sind, substituiert: K882, das sich innerhalb 
eines konservierten Sumoylierungsmotives befindet, und K868 und K 872, die nahe 
dieser  Konsensussequenz  lokalisiert  sind.  Dazu  wurden  verschiede  Mutanten 
hergestellt, in denen ein oder mehrere dieser Aminosäurerest(e) durch Argininreste 
(R)  ersetzt  wurden  (KR-Mutanten).  Diese  wurden  anschließend  in  einem 
Sumoylierungsexperiment  auf  ihre  Modifizierbarkeit  hin  untersucht.  Die Punktmutante  mGluR8a-C-K882R  und  die  Mutante,  in  der  alle  drei  Lysinreste 
substituiert worden waren, konnte nicht sumoyliert werden, während für mGluR8a-C-
Proteine  mit  Einzel-  oder  Doppelmutationen  der  Lysine  K868  und  K872  eine 
Sumoylierung  weiterhin  nachweisbar  war.  Daraus  lässt  sich  schließen,  dass  in 
mGluR8a-C spezifisch der Lysinrest 882 sumoyliert wird. 
 
Zusammengefasst konnte in der vorliegenden Arbeit konnte die E3-Ligase Pias1, die 
wichtig für den Prozess der Sumoylierung ist, als Interaktionspartner von mGluR8 
und  anderer  Gruppe  III  mGluRs  identifiziert  werden.  Weiterhin  konnte  gezeigt 
werden,  dass  diese  Interaktion  funktionell  bedeutsam  ist,  da  der  C-Terminus  von 
mGluR8 in vivo spezifisch am Lysinrest 882 durch Sumoylierung modifiziert wird. In 
weiterführenden  Experimenten  gilt  es  nun  zu  untersuchen,  ob  auch  der  intakte 
Rezeptor in vivo durch Sumoylierung modifiziert wird. 
 Identifikation  und  Charakterisierung  intrazellulärer  Interaktionspartner  des  metabotropen 
Glutamatrezeptors mGluR8 
 
Die presynaptischen metabotropen Glutamat-Rezeptoren der Gruppe III (mGluRs) spielen eine 
zentrale  Rolle  in  der  Regulation  presynaptischer  Aktivität  über  G-Protein-Effekte  auf 
Ionenkanäle und signalübertragende Enzyme. Wie alle G-Protein-gekoppelten Rezeptoren der 
Klasse  C  hat  auch  mGluR8  eine  verlängerte  intrazelluläre  C-terminale  Domäne  (CTD),  die 
vermutlich die Modulation nachgeordneter Signale erlaubt. In einem Hefe-Zwei-Hybrid-Screen 
einer  cDNA-Bibliothek  aus  adultem  Rattenhirn,  in  welchem  CTDs  vom  mGluR8a  und  8b 
(mGluR8-C)  als  “Köder”  verwendet  wurden,  konnten  neben  anderen  Proteinen  verschiedene 
Komponenten  der  Sumoylierungskaskade  (ube2a,  sumo-1,  Pias1,  Piasα,  Piasxβ)  als 
Interaktionspartner  identifizieret  werden.  Bindungsexperimente  mit  rekombinanten  GST-
Fusionsproteinen bestätigten, daß Pias1 nicht nur mit mGluR8-C, sondern mit allen Gruppe III 
mGluR  CTDs  interagiert.  Die  Pias1-Bindung  an  mGluR8-C  benötigt  eine  N-terminal  des 
Sumoylierungs-Konsensusmotivs liegende Region und wird nicht beeinträchtigt durch Arginin-
Austausch des innerhalb dieser Region liegenden, konservierten Lysin-Restes K882. 
Kotransfektionsexperimente mit fluoreszenzmarkiertem mGluR8a-C, Sumo1 und Enzymen der 
Sumoylierungskaskade in HEK293-Zellen zeigten, daß mGluR8a-C in vivo sumoyliert werden 
kann.  Der  Arginin-Austausch  des  Lysin-Restes  K882,  jedoch  nicht  Austausche  von  anderen 
konservierten Lysin-Resten innerhalb der CTD-Domäne, verhinderte die in vivo Sumoylierung. 
Unsere  Ergebnisse  deuten  darauf  hin,  daß  die  posttranslationale  Sumoylierung  einen  neuen 
Mechanismus der Gluppe III mGluR Regulation darstellt. 
 
 
Schlüsselwörter:  Metabotrope  Glutamat-Rezeptoren,  Pias1,  Sumoylierung,  Hefe-Zwei-Hybrid, 
Ubiquitin konjugierendes Enzym 9, Sumo-1                               
 
ABSTRACT 
 
 
Group III presynaptic metabotropic glutamate receptors (mGluRs) play a central 
role in regulating presynaptic activity through G-protein effects on ion channels and 
signal transducing enzymes. Like all Class C G-protein coupled receptors, mGluR8 
has  an  extended  intracellular  C-terminal  domain  (CTD)  presumed  to  allow  for 
modulation of downstream signaling. To elucidate the function and modulation of 
mGluR8,  yeast  two-hybrid  screens  of  an  adult  rat  brain  cDNA  library  were 
performed  with  the  CTDs  of  mGluR8a  and  8b  (mGluR8-C)  as  baits.  Different 
components of the sumoylation cascade (ube2a, sumo-1, Pias1, Piasγ and Piasxβ) 
and some other proteins were identified as mGluR8 interacting proteins. Binding 
assays using recombinant GST-fusion proteins confirmed that Pias1 interacts not 
only with mGluR8-C, but all group III mGluR CTDs. Pias1 binding to mGluR8-C 
required  a  region  N-terminally  to  a  consensus  sumoylation  motif  and  was  not 
affected by arginine substitution of the conserved lysine K882 within this motif. Co-
transfection  of  fluorescently  tagged  mGluR8a-C,  sumo-1  and  enzymes  of  the 
sumoylation  cascade  into  HEK  293  cells  showed  that  mGluR8a-C  can  be 
sumoylated  in  cells.  Arginine  substitution  of  lysine  K882  within  the  consensus 
sumoylation motif, but not of other conserved lysines within the CTD, abolished in 
vivo  sumoylation.  The  results  are  consistent  with  post-translational  sumoylation 
providing a novel mechanism of group III mGluR regulation. 
 
Keywords: Metabotropic glutamate receptor, Pias1, sumoylation, yeast two-hybrid, 
ubiquitin conjugating enzyme 9, sumo-1 
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 ABBREVIATIONS 
 
AA  amino acid 
APPBP1  amyloid beta precursor protein-binding protein 1 
ATP  adenosine-triphosphate 
bp  base pair 
BSA  bovine serum albumin 
CFP  cyan fluorescent protein 
cGMP  cyclic guanosine monophosphate 
CMV  cytomegalovirus 
CtBP  C-terminal binding protein of adenovirus E1A 
CTD  carboxyl terminal domain 
Da  dalton 
DMEM  dulbecco’s modified essential medium 
DMSO  dimethylsulfoxide 
DNA  desoxyribonucleic acid 
dNTP  deoxyribonucleoside-5’-triphosphate 
DTT  dithiothreitol 
EDTA  ethylenediamine tetra acetic acid 
EGTA  ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-
tetraacetic acid 
FCS  fetal calf serum 
g  gram 
Gal  galactose  
GFP  green fluorescent protein 
Glc  glucose 
GLUT  glucose transporter 
GPCR  G-protein coupled receptor 
GPI  glycosyl phosphatidylinositol 
GST  glutathione-S-transferase 
HECT  homologous to E6AP carboxyl terminus 
HEK293  human embryonic kidney 293 cells 
HPLC  high performance liquid chromatography 
hr  hour 
HRP  horseradish peroxidasel-β-d-thiogalactopiranoside 
-HUWL  medium short of histidine (H), uracil (U),  tryptophan (W) 
and leucine (L) 
L  liter 
Ig  immunoglobulin 
IPTG  isopropyl-β-thiogalactopyranoside 
L-AP4  l(+)-2-amino-4-phosphonobutyric acid 
LB  luria bertani 
LiAc  lithium acetate  
MBP  maltose binding protein 
min  minute 
mg  milligram 
mGluR  metabotropic glutamate receptor 
Nedd8  neural precursor cell expressed, developmentally down-
regulated 8 
NaOAc  sodium acetate  
 
OD  optical density 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PEG  polyethylene glycol 
Pias  protein inhibitor of activated STATs (signal transduction 
and activator of transcription) 
Raf  raffinose 
RanBP2  ran binding protein 2 
RanGAP1  ran GTPase-activating protein 
RING  really interesting new gene 
RNA  ribonucleic acid 
rpm  revolutions per minute 
RT  room temperature 
SAF  serum amyloid A activating factor 
SAP domain  SAF-A/B acinus and Pias domain 
SBM  sumo-binding motif 
SD  synthetic dropout medium 
SDS  sodium dodecyl sulphate 
s  second 
Siah  seven in absentia homolog 
sumo  small ubiquitin related modifier 
TE  Tris-EDTA buffer 
TEMED  N,N,N’,N’-tetramethylethylendiamin 
Tris  tris-hydroxymethyl-aminomethane 
ubc  ubiquitin conjugating enzyme 
Ubl  ubiquitin-like modifier 
UbL  ubiquitin-like domain 
UV  ultraviolet 
v/v  volume to volume 
w/v  weight to volume 
X-Gal  5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
YFP  yellow fluorescent protein. 
YPD  yeast growing medium containing 1% (m/v) yeast extract, 
2% (m/v),  peptone and 2% (m/v) dextrose.   1 
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1  INTRODUCTION 
Glutamate, a major excitatory neurotransmitter in the brain, exerts its effects through 
two distinct classes of receptors, the ionotropic (NMDA, AMPA and kainate) and 
metabotropic  glutamate  receptors  (mGluRs)  (Conn  and  Pin,  1997).  As  shown  in 
Figure  1,  ionotropic  glutamate  receptors  localize  at  postsynaptic  density  sites  and 
mediate  quick  responses  upon  glutamate  binding.  mGluRs  are  distributed  in 
perisynaptic areas (both pre- and postsynaptically), coupled to G-proteins and contain 
seven-transmembrane domains. They are structurally distinct from family A and B G-
protein  coupled  receptors  (GPCRs),  as  they  possess  a  large  extracellular  ligand 
binding domain and an extended intracellular C-terminus and therefore were defined 
as a new family of GPCRs (Conn and Pin, 1997; Sachdev et al., 2001). mGluRs have 
been  implicated  in  the  regulation  of  transmitter  release,  short  and  long  term 
modulation of synaptic transmission, neuronal development and synaptic plasticity 
(Nakanishi, 1994; Nakanishi et al., 1994; Pin and Duvoisin, 1995; Conn and Pin, 
1997; Nakanishi et al., 1998).  
At least eight different mGluR isoforms have been identified and are classified into 
three  subgroups  based  on  sequence  homology,  downstream  effectors  and  agonist 
specificity.  Group  I  receptors  (mGluR1  and  5)  are  positively  coupled  to 
phospholipase C, whereas group II (mGluR2 and 3) and group III (mGluR4, 6, 7 and 
8)  receptors  typically  inhibit  activated  adenylate  cyclase  activity  (Conn  and  Pin, 
1997). Group I mGluRs are mainly located around postsynaptic density, and involved 
in synaptic plasticity including LTP and LTD (long-term potentiation and depression) 
(Aiba et al. 1994a, b. Lu et al. 1997). Group II and III mGluRs are distributed mainly 
around presynaptic active zone, with differently regional distributions and different 
functions in the brain. One of the group II receptors, mGluR2, has also been found to 
be linked to LTD (Yokoi et al. 1996). Another group II receptor, mGluR3, is widely 
expressed  in  glial  cells  and  related  to  neurotropin  release  from  the  glial  cells 
(Ciccarelli  et  al.  1999).  Apart  from  mGluR6,  which  is  found  both  pre-  and  post-
synaptically  but  only  in  the  retina,  group  III  mGluRs  are  mostly  localized 
presynaptically throughout the brain. mGluR4, 7 and 8 differ in their distributions in 
the brain and affinities to Glu and other agonists and antagonists (Shigemoto et al., 
1997; Conn and Pin, 1997).    4 
Many group- and subtype-specific mGluR agonists and antagonists have been found 
and  applied  to  both  basic  research  and  clinical  treatment  of  anxiety  disorders  in 
human  (Conn  and  Pin,  1997;  Swanson  et  al.,  2005).  For  all  mGluRs  except  for 
mGluR3,  mice  deficient  for  single  mGluR  genes  have  been  studied.  The 
classification, characterization and knockout phenotypes of all known mGluRs are 
listed in table 1.  
 
Figure 1. Hypothetical synapse illustrating the general synaptic localization and function of 
glutamatergic receptors and transporters. The ionotropic glutamate receptors (NMDA, kainate 
and AMPA subtypes) largely function to mediate fast receptor transmission, but also mediate 
the changes required for neuronal plasticity. The vesicular transporters (vGluT1 and vGluT2) 
load glutamate into vesicles presynaptically. The glial, astrocyte and postsynaptic glutamate 
transporters EAATs (excitatory amino-acid transporters) are thought to mediate the uptake of 
glutamate  and  therefore  termination  of  synaptic  transmission.  The  metabotropic  glutamate 
receptor 1-8 have a diverse synaptic localization and function pre- and postsynaptically to 
modulate neurotransmitter release and postsynaptic excitability, respectively. This figure is 
taken from Swanson et al. (2005). 
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Table 1. Classification and characterization of mGluRs 
 
Receptor 
family  
Coupling  Trans- 
duction 
Key localization and actions  Group/subtype-selective 
pharmacological agents 
Knockout Phenotype 
(References) 
Group I           
mGluR 1  Excitatory 
Gq-coupled 
PLC  Enriched postsynaptically at 
glutamatergic synapses. Indicated in 
synaptic plasticity, including long-
term potentiation /depression 
(LTP/LTD). Cerebellar localization 
in granular cell and parallel fibre 
layers.  
Agonists: DHPG, 1S,3R-
ACPD, quisqualate 
Antagonist: LY393675 
Allosteric antagonist: 
LY367385 
 
Viable but show characteristic cerebellar symptoms such as 
ataxic  gait  and  intention  tremor.  The  anatomy  of  the 
cerebellum  and  hippocampus  is  normal.  LTD  is  clearly 
deficient in cerebellum and LTP is substantially reduced in 
hippocampus. A moderate level of impairment is observed 
in context-specific associative learning (Aiba et al., 1994a; 
Aiba et al., 1994b). 
mGluR 5  Excitatory 
Gq-coupled 
PLC  Most often postsynaptic at 
glutamatergic synapses, also found in 
glial cells. High expression in several 
forebrain regions including 
hippocampus and amygdala. 
Implicated in synaptic plasticity, 
especially some forms of cortical and 
hippocampal LTD. 
Agonists: DHPG, 1S,3R-
ACPD, quisqualate, 
CHPG 
Allosteric antagonist: MPEP 
 
Weight  is  significantly  less  than  littermate  controls.  The 
gross  anatomy  and  development  of  CNS  is  normal.  LTP 
was significantly reduced in the NMDA receptor dependent 
pathways such as the CA1 region and dentate gyrus. The 
mutant mice were also impaired in the acquisition and use 
of spatial information in both the Morris water maze and 
the fear-conditioning test (Lu et al., 1997; Bradbury et al., 
2005). 
Group II           
mGluR 2  Inhibitory  
Gi/Go -
AC  Localization largely presynaptic on 
glutamatergic and other 
Agonists: DCG-IV, 2R,4R-
APDC, 1S,3R-ACPD, 
No histological changes and no alterations in basal synaptic 
transmission,  paired-pulse  facilitation,  or  tetanus-induced   6 
coupled  neurotransmitter synapses. High 
expression in forebrain regions 
including hippocampus and 
amygdala; also in certain layers 
within the cortex and cerebellum. 
Linked to hippocampal LTD and 
regulation on medial perforant path. 
LY354740, LY379268 
Antagonist: LY341495 
Potentiator: 4-MPPTS 
(LY487379), 4-APPES, 
CBiPES 
long-term  potentiation  (LTP)  at  the  mossy  fiber-CA3 
synapses.  Long-term  depression  (LTD)  induced  by  low-
frequency stimulation, however, was almost fully abolished 
(Yokoi et al., 1996).  
mGluR 3  Inhibitory  
Gi/Go -
coupled 
AC  Widely expressed in glial cells but 
also discrete localization both pre- 
and postsynaptic on glutamatergic 
and other neurotransmitter synapses. 
Expression within forebrain regions 
including hippocampus and 
thalamus. Linked to neurotropin 
release from glial cells. 
Agonists: DCG-IV, 2R,4R-
APDC, 1S,3R-ACPD, 
LY354740, LY379268 
Antagonist: LY341495 
No report. 
Group III           
mGluR 4  Inhibitory  
Gi/Go -
coupled 
AC  Localization both pre- and 
postsynaptic on glutamatergic and 
other neurotransmitter synapses. 
Presynaptic in cerebellar parallel 
fibres and linked to cerebellar 
plasticity and motor learning. 
Agonists: L-SOP, ACPT-1, 
L-AP4 
Antagonist: MSOP, MAP4, 
CPPG 
No gross motor behaviour abnormalities. Deficient on the 
rotating rod motor-learning  test,  suggesting  the KO mice 
may have an impaired ability to learn complex motor tasks. 
Paired-pulse facilitation and post-tetanic potentiation were 
impaired. In contrast, long-term depression (LTD) was not 
impaired.    Resistant  to  absence  seizures  induced  by 
GABAAR antagonists.    7 
(Pekhletski et al., 1996; Snead et al., 2000) 
mGluR 6  Inhibitory  
Gi/Go -
coupled 
AC  Expression confirmed only in retinal 
bipolar ON cells.  
Agonists: L-SOP, L-AP4 
Glutamate-site  
antagonist: MSOP, MAP4 
 
No obvious changes  in retinal  cell organization or in  the 
projection  of  optic  fibers  to  the  brain.  The  homozygous 
mutant mice showed a loss of ON responses but unchanged 
OFF responses to light (Masu et al., 1995). 
mGluR 7  Inhibitory  
Gi/Go -
coupled 
AC  Localization both pre- and 
postsynaptic on glutamatergic and 
other neurotransmitter synapses in 
limbic and cortical regions. Has 
lower affinity for glutamate than 
other mGluR subtypes and only 
presynaptic inhibitory mGluR 
localized to active zone of synapses. 
Thought to serve a classical 
autoreceptor function. 
Agonists: L-SOP, L-AP4 
Antagonist: MSOP, MAP4, 
LY341495 
(100-fold lower affinity than 
group II) 
 
Significantly  reduced  levels  in  immediate  postshock  and 
delayed  freezing  responses.  The  knockout  mice  were 
normal  in  pain  sensitivity  and  locomotor  activity.  In 
conditioned taste aversion (CTA) experiments, the KO mice 
failed  to  associate  between  the  taste  and  the  negative 
reinforcer in CTA experiments. Again, the knockout mice 
showed  no  abnormalities  in  taste  preference  and  in  the 
sensitivity to LiCl toxicity (Masugi et al., 1999).  
Increased  susceptibility  to  pentylenetetrazole-induced 
seizures (Sansig et al., 2001). 
mGluR 8  Inhibitory  
Gi/Go -
coupled 
AC  Localization largely presynaptic on 
glutamatergic and other 
neurotransmitter synapses. High 
expression in forebrain regions 
including hippocampus and 
amygdala. Linked to regulation of 
lateral perforant path. 
Agonists: L-SOP, L-AP4, 
(S)3,4-DCPG 
Antagonist: MSOP, MAP4 
Blunted  response  to  novelty  and  increased  anxiety-like 
behaviors.  Increased  c-Fos  expression  in  thalamus 
centromedial nucleus, and overweight (Linden et al., 2002; 
Linden et al., 2003b; Duvoisin et al., 2005). 
The table is modified from Swanson et al. (2005).   8 
First  mGluR8a  was  cloned  from  mice  (Duvoisin  et  al.,  1995),  and  two  alternatively 
spliced forms of mGluR8, designated HmGluR8b and HmGluR8c, were cloned from a 
human fetal brain cDNA library (Malherbe et al., 1999). The HmGluR8b and c receptors 
differ from a HmGluR8a by out-of-frame insertions, which result in substitution of the 
last 16 amino acids in the C-terminus of HmGluR8a with 16 different amino acids in 
HmGluR8b, and termination of the polypeptide before the putative seven transmembrane 
domains of HmGluR8c. Thus, the predicted HmGluR8c protein is 501 amino acids long 
and could represent a secreted isoform.  
RT-PCR, Northern blot and in situ hybridization studies showed that both HmGluR8a 
and b are expressed with similar abundance in fetal and adult brains. In situ hybridization 
revealed prominent mGluR8 mRNA expression in olfactory bulb, pontine gray, lateral 
reticular  nucleus  of  the  thalamus,  and  piriform cortex.  Less  abundant  expression  was 
detected in cerebral cortex, hippocampus, cerebellum and mammillary body (Duvoisin et 
al., 1995; Saugstad et al., 1997). In the lateral reticular and ambiguous nucleus, only 
mGluR8a mRNA is found (Corti et al., 1998). The in situ hybridization results indicate 
that HmGluR8c is predominantly expressed in glial cells in the human brain (Malherbe et 
al., 1999). mGluR8 is also expressed in the enteric nervous system (Liu et al., 1997), 
pineal gland (Moriyama et al., 2000) and glucagon-secreting α-cells and intrapancreatic 
neurons in the pancreas islet (Tong et al., 2002). Rat microglia also expresses mGluR8 
mRNA  and  receptor  protein,  together  with  mGluR4  and  mGluR6,  but  not  mGluR7 
(Taylor et al., 2003). Immunocytochemical data demonstrate that mGlu8 receptors are 
mainly located presynaptically (Shigemoto et al., 1997), but in the retina they are also 
found  post-synaptically  (Koulen  and  Brandstatter,  2002).  Recently  it  was  found  that 
mGluR8  is  not  only  expressed  in  glutamatergic  but  also  GABAergic  synapses  in 
periaqueductal gray matter (Marabese et al., 2005).  
mGluR8 KO mice with deletion of both mGluR8a and mGluR8b have been generated 
(Linden et al., 2002; Duvoisin et al., 2005). The overall morphology of mGluR8 KO mice 
is normal. No differences in comparation to wild type animals were observed in eye 
reflexes,  auditory  reflexes,  respiratory  rate,  body  temperature,  salivation,  urination, 
defecation, skin color or irritability. Similarly, no differences were observed in stance, 
limb strength, placing, grasping, righting, tail pinch, and tail-flick latency (Linden et al.,   9 
2002). But mGluR8 KO mice exhibit increased anxiety-related behaviour in the elevated 
plus maze test (Linden et al., 2002), and this increase is accompanied by increased c-FOS 
expression  in  the  centromedial  nucleus  of  the  thalamus  (Linden  et  al.,  2003b).  The 
mGluR8 KO mice are also slightly overweight and mildly insulin resistant (Duvoisin et 
al., 2005). 
Despite  numerous  pharmacological  in  vivo  studies  and  the  generation  of  mGluR8 
knockout mice (Thomas et al., 2001; Pothecary et al., 2002; Linden et al., 2003a; Schmid 
and Fendt, 2005), still little is known about the function of this receptor. The aim of this 
study is to find intracellular proteins that may regulate mGluR8 function. Yeast two-
hybrid screens were performed with baits corresponding to the intracellular C-terminal 
domains of both mGluR8a and mGluR8b. About 30 candidate interacting proteins were 
identified, including proteins related to sumoylation: sumo-1, an E2 protein ube2a, and 
three E3 proteins Pias1, Piasxβ and Piasγ. Sumoylation is a type of modification in which 
the  sumo  protein  is  covalently  conjugated  onto  a  Lys  residue  of  a  substrate,  and  is 
catalysed by three enzymes: activating enzyme E1, conjugating enzyme E2 and ligase E3. 
Sumoylation has been shown to modify a large number of proteins with important roles 
in  many  cellular  processes  including  gene  expression,  chromatin  structure,  signal 
transduction, and maintenance of the genome (Gill, 2004). A review on sumoylation is 
attached  as  Appendix  I1.  The  interaction  between  Pias1  and  group  III  mGluRs  was 
verified  by  binary  yeast  two-hybrid  assays  and  GST  pulldown.  In  vivo  sumoylation 
assays including mutations of the receptor proved that the mGluR8a-C protein could be 
sumoylated at K882. While ubiquitination of GPCRs is a well-documented phenomenon 
(Marchese and Benovic, 2004) and appears to play a role in group I mGluR degradation 
(Moriyoshi et al., 2004), the related but functionally distinct sumoylation cascade has not 
yet  been  linked  to  any  plasma  membrane  receptor.  Thus,  the  results  of  this  thesis 
represent the first evidence for sumo-conjugation of a GPCR.    10 
2  MATERIALS AND METHODS  
2.1  Chemicals  
All  chemicals,  unless  otherwise  stated,  were  ordered  from  the  following  companies: 
Roche Diagnostics, Eppendorf, Fluka, Gibco-BRL, Merck, Sigma and Roth. Solutions 
were prepared with Milli-Q water (Millipore).  
Restriction enzymes were ordered from Roche Diagnostics or New England Biolabs.  
 
2.2  Kits 
Preparations of plasmid DNA, purifications of DNA from either PCR products or agarose 
gels, and substitutions of lysine to arginine of mGluR8a-C constructs were performed 
according to the protocols provided with the following kits.  
 
•  QIAprep Spin Miniprep Kit (QIAGEN). 
•  QIAGEN Plasmid Midi Kit (QIAGEN). 
•  QIAGEN Plasmid Maxi Kit (QIAGEN).  
•  QiaQuick PCR Purification Kit (QIAGEN). 
•  Perfectprep Gel Cleanup Kit (Eppendorf).  
•  QuikChange Site-Directed Mutagenesis Kit (Strategene). 
 
 
2.3  Oligonucleotides  
Oligonucleotides  (Table  2)  were  ordered  from  the  company  MWG,  delivered  as 
lyophilized pellets and dissolved in HPLC water to a final concentration of 100 pmol/µl. 
 
2.4  DNA Constructs 
The constructs listed in Table 3 were generated by cloning the fragments from either 
other plasmids or PCR products, or by using site-directed mutagenesis (Stratagene). The 
constructs were checked by DNA sequencing, restriction digestions, or Western blotting 
for proteins expressed in either bacterial or mammalian cells (Appendix I). 
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Table 2. List of primers for PCR or sequencing reactions 
 
 
Primer names  Sequence (5’---3’) 
Aos1EcoRIATGHis,  s  CGGAATTCCATGGGCAGCAGCCATCATC  
Aos1-XbaI-end, as   GCTCTAGATCAGTTTTCCTTGCCTGGAGATG  
DsRed2-C1-seq-1132,  s  CTGGTGGAGTTCAAGT C  
Lib-1, library cloning,  s-1  CTTGCTGAGTGGAGATGCCTCC  
Lib-2, library cloning,  as  CTGGCAAGGTAGACAAGCCGAC  
Lib-3, library cloning,  s-2  TTATGATGTGCCAGATTATGC  
m4b truncate B1, as  GCGTCGACTCAAAAGAGTTGGTGGATGAAG C  
m4b truncate F2,  s  GCGAATTCCACCACGTTGCAAAAGAG  
m4b, as   GCGTCGACTCAGAGACCATCACCAAACA 
m4b,  s  GCGAATCCCATATTTTTCCATTCTGCTC C  
m8 EcoRI-ATG, 56,  s  GCGAATTCAATGGTATGCGAGGGAAAGC G  
m8 K882R, as   GACTCTCACAGAGTTCAGATCTCACCTCGCCATTTG 
m8 K882R,  s  CAAATGGCGAGGTGAGATCTGAACTCTGTGAGAGTC  
m8K868-872R,  as  GGTCTGTCATTTCCCCTTTGGATCAGTCTGCTTTGCA
TGGTAG 
m8K868-872R,  s  CTACCATGCAAAGCAGACTGATCCAAAGGGGAAATG
ACAGACC  
m8N24SalI, 54, as  TGCGGTCGACTCAGCTTTGCATGGTAGCAGCTGTG 
m8seq-end, 2596, s   CATCCAGAGCAGAATGTTC  
m8seq-start, 232,  as  CATGAACAGGAAAAAGACC  
m8tailEcoRI, 57, s   GGAATTCCATCCAGAGCAGAATGTTCAAAAAC  
m8tailSalI, 52, as   TGCGGTCGACTCAGATCGAATGATTACTGTAGCTG  
m8tC44EcoRI, 57, s   GGAATTCATGCAAAGCAAACTGATCCAAAAG 
mGluR8aK868R, 64,  as  CCCTTTTGGATCAGTCTGCTTTGCATGGTAG 
mGluR8aK868R, 64,  s  CTACCATGCAAAGCAGACTGATCCAAAAGGG 
mGluR8aK872R, 64,  as  GGTCTGTCATTTCCCCTTTGGATCAGTTTGC  
mGluR8aK872R, 64,  s  GCAAACTGATCCAAAGGGGAAATGACAGACC  
Myc-m8-2, as   GGATGGAATGGGCATACTCGAGGTCCTCCTCGCTGA
TCAGCTTCTGCTCTTGGCTGTGAGTTC  
Myc-m8-2,  s  GAACTCACAGCCAAGAGCAGAAGCTGATCAGCGAG
GAGGACCTCGAGTATGCCCATTCCATCC  
pQE  seq  AAACAAATAGGGGTTCC  
SGT truncate B1, as  GCCTCGAGTCACTCAGCTGAGTCCTCCTCA G  
SGT truncate B2, as  GCCTCGAGTCAGAGGTTGGACTTGTACGT G  
SGT truncate B3, as  GCCTCGAGTCACTCTTGCTGCTCCTCGTG 
SGT truncate F1,  s  GCGAATTCGACAACAGGAAGCGCCTGG 
SGT truncate F2,  s  GCGAATTCGCAGAGCGCCTTAAAACAGAAG 
SGT truncate F3,  s  GCGAATTCGACACGTACAAGTCCAACCT C  
SUMO1 C4HindIII, 60,  as  CCCAAGCTTACCCCCCGTTTGTTCCTGATAAAC  
SUMO-HindIII, as  CCCAAGCTTCTAAACCGTCGAGTGACCCC C  
ube2iclone-BamHI, rat, 60C, s   CGGGATCCATGTCGGGGATTGCCCTCAGC  
ube2iclone-HindIII, 60C,  as  CCCAAGCTTATGAGGGGGCAAACTTCTTCGC  
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2.5  Yeast Two-Hybrid 
The  following  protocols  describe  the  two-hybrid  screen  for  proteins  interacting  with 
mGluR-8a-C. The screens for mGluR8b-C and mGluR4b-C were performed in the same 
way. 
 
2.5.1  Materials for Yeast Two-hybrid 
Yeast strains  
Table 3. List of DNA  constructs 
 
constructs  inserts  5' site  3' site 
pcDNA3-His-aos1 
PCR  product  via  pET28aHIS-
aos1   EcoRI  Xho  I 
pECFP-C1-sumo1 
PCR product via pJG4-5-ubl1 (rat 
brain library)  BamHI/Bgl  II  HindIII 
pECFP-C1-ube2i 
PCR  product  via  pJG4-5-ube2a 
(rat brain library)  BamHI/Bgl  II  HindIII 
pEGFP-C2 mGluR8a-C44  PCR product   EcoRI  Sal  I 
pEGFP-C2 Pias1  mouse pias1  Bgl  II  HindIII 
pEGFP-C2-8a-N24  PCR product   EcoRI  Sal  I 
pEGFP-mGluR8a-C-
K868&872R  site-directed mutagenesis     
pEGFP-mGluR8a-C-K872R  site-directed mutagenesis     
pEGFP-mGluR8a-C-K882R  mGluR8a-CT-K882R     
pEGFP-mGluR8a-C-K868R  site-directed mutagenesis     
pEYFP-C1-sumo1 
PCR product via pJG4-5-ubl1 (rat 
brain library)  BamHI/Bgl  II  HindIII 
pEYFP-C1-ube2i 
PCR  product v ia  pJG4-5-ube2i 
(rat brain library)  BamHI/Bgl  II  HindIII 
pGEX5X-1-mGluR8a-C-
K882R  site-directed mutagenesis     
pMAL-c2-Pias1  mouse pias1  BamHI  HindIII 
pMAL-c2-ube2i  ube2i (rat brain library)     
pMAL-c2-Pias  (fragment)  Pias  (rat brain library)     
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EGY48: MATα trp1 his3 ura3 leu2::6 LexAop-LEU2  
RFY206: MATa trp1Δ::hisG his3Δ200 ura3-52 lys2Δ201 leu2-3 (mating strain)  
Reporter gene (LacZ) plasmids   
pSH18-34 URA3, Amp
r, 8 ops-LacZ  
pJK101 URA3, Amp
r, GAL1-2 op-LacZ (used in repression assay for nuclear transport)  
Bait plasmid  
PGilda: HIS3, Amp
r, inducible GAL1 promoter, expresses LexA(1–202) as DNA binding 
domain followed by a polylinker for making bait fusion protein. 
Target plasmid  
pJG4-5:  TRP1,  Amp
r,  inducible  GAL1  promoter,  expresses  B42-HA  tag  as  a 
transcriptional  activation  domain  followed  by  a  polylinker  for  making  target  fusion 
protein expression libraries. 
Medium 
All media were prepared according to the User’s Manual (OriGene Tech. Inc. Version 
1.2). 
 
2.5.2  Small-scale Yeast Transformation  
Yeast cells from a single clone were cultured in 200 ml of YPD medium with shaking at 
250 rpm until OD600 reached 0.8-0.9. After pelleting twice and resuspending first in 50 ml 
of TE buffer and then in 1 ml TE/LiAc solution, 2 µg of each plasmid DNA and 2 mg of 
herring testis carrier DNA were added to 0.1 ml of the yeast suspension and mixed well 
by vortexing, followed by addition of 0.6 ml of sterile PEG/LiAc and vortexing at high 
speed for 10 sec. The mixture was incubated for 30 min at 30°C with shaking at 200 rpm, 
and then mixed gently with 70 µl of DMSO. After 15 min heat shock in a 42°C water 
bath, the cells were chilled in ice-water mixture for 2 min, then pelleted, diluted with TE 
buffer and spread on SD/Glc/-UH agar plates. The plates were incubated at 30°C for 
about three days until the clones grew up to 0.5 mm in diameter. 
 
YPD: 10 g/L Yeast extract, 20 g/L Peptone, 20 g/L Dextrose (Glucose). 
TE: Tris-HCl (0.01 M, pH 7.5)- EDTA (1 mM). 
TE/LiAc: 0.1 M LiAc(lithium acetate) in TE.   14 
PEG/LiAc: 40% (w/v) PEG 4000 (polyethylene glycol, MW 3,350) in TE/LiAc. 
SD  medium:  Minimal  Synthetic  Dropout  medium.  Comprised  of  a  nitrogen  base,  a 
carbon source (glucose or galactose), and a DO* supplement without some of histidine (-
H), tryptophan (-W), uracil (-U) and Leucine (-L).  (*DO: Dropout supplement; a mixture 
of  specific  amino  acids  and  nucleosides  used  to  supplement  SD  base  to  make  SD 
medium;  DO  solutions  are  missing  one  or  more  of  the  nutrients  required  by 
untransformed yeast to grow on SD medium). 
 
2.5.3  Large-scale Yeast Transformation  
1000  ml  of  YPD  medium  were  used  to  dilute  a  150  ml  overnight  culture  of 
EGY48/pSH18-34/pGilda-mGluR8a-C in SD/Glc/-UH medium, and incubated at 30 
oC 
for  about  6  hr  until  OD600  had  reached  0.8-1.0.  The  cells  were  then  pelleted  and 
resuspended  three  times,  in  H2O  for  the  first  two  times  and  20  ml  TE/LiAc  at  last, 
followed by mixture with 2.5 mg cDNA library (Origene) and 20 mg denatured carrier 
DNA. The mixture was transferred to a 500 ml glass flask containing 150 ml PEG/LiAc, 
and incubated at 30 °C with shaking at 200 rpm. After 30 min, 17.5 ml DMSO were 
added and mixed gently. The cells were heat-shocked for 15 min at 42 °C with gentle 
shaking every 2-3 minutes and then chilled for 5 min in an ice-water mixture. At last, the 
cells were pelleted, resuspended in 16 ml TE buffer and spread on SD/Glc/-UHW plates. 
The plates were incubated at 30 °C for three to four days until the clones grew up to 0.5 
mm in diameter.  
 
2.5.4  Filter Assay  
Yeast clones were streaked on one plate, grown for two days, imprinted on a piece of 
nitrocellulose membrane and frozen in liquid nitrogen. The membrane was placed on a 
Whatman  filter  paper  soaked  with  X-Gal.  The  time  scale  of  the  color  change  was 
recorded. 
 
2.5.5  Screen under Selective Conditions  
Cotransformant yeast cells that had been stored at -70 
oC were put on ice for about 30 
min for recovery, then diluted in TE buffer and incubated for 4 hr at 30 °C with rotation.   15 
The cells were spread on SD/Gal/Raf/-UHWL/X-Gal plates and incubated at 30 °C for 
three days. Blue colonies were streaked on fresh SD/Gal/Raf/-UHWL/X-Gal plates.  
 
2.5.6  Yeast Mating  
EGY48 and RFY206 yeast cells with different plasmids were added into the same tube 
with 0.5 ml YPD medium and incubated for 6 hr at 30°C on a rotator set at 150 rpm. The 
cells were pelleted, spread on plates and incubated for 3–5 days at 30°C in order to allow 
diploid cells to form visible colonies. 
 
2.5.7  Isolation of Plasmid DNA from Yeast Cells 
5 ml of yeast cell suspension were pelleted and lysed by vortexing for 2 min in 200 µl of 
yeast lysis solution, mixed with 300 mg glass beads (0.25-0.5 µm in diameter) and 200 µl 
PCI (Phenol/Chloroform/Isoamyl alcohol 25/24/1 (v/v/v)). After centrifugation at 14,000 
rpm for 5 min, the DNA in the upper phase was precipitated by mixing with 1/10 volume 
of 3 M NaOAc (sodium acetate, pH 5.2), then 2.5 times volumes of absolute ethanol, 
followed by centrifugation for 5 min at 14,000 rpm. The pellet was washed with 70%  
(v/v) ethanol, dried with SpeedVac vacuum and redissolved in 20 µl H2O.  
 
Yeast lysis solution 
Triton X-100, 2% (v/v) 
SDS, 1% (w/v) 
NaCl, 0.1 M 
EDTA, 1.0 mM 
Tris, 0.01 M, pH 8.0 
 
2.5.8  Amplification of Prey Fragments  by PCR 
Yeast cells were lysed by alternate freeze-thawing in liquid nitrogen and water for three 
times, and used for standard PCR reactions to amplify the inserts in the prey plasmids. 
 
PCR mixture included: 
Lysed yeast cells in H2O  20  µl    16 
10 x PCR buffer     5  µl 
Primer Lib-1, s      0.5  µl 
Primer Lib-2, as     0.5  µl 
dNTP mixture (10 mM)   1  µl 
MgCl2 (50 mM)     1.5  µl 
H2O        21.25  µl 
Taq polymerase     0.25  µl  
Total volume      50  µl 
 
Cycling was set as: 
 
Stage  Step  Temperature (°C)  Time (min)  Number of cycles 
I  1  94  5  1 
II  1  94  1 
  2  58  1 
  3  72  2.5 
 
30 
III  1  72  10  1 
Hold    4     
 
 
2.6  DNA Sequencing 
PCR products purified with QIAquick PCR Purification kit (Qiagen), or plasmid DNA purified 
with Qiagen kits (see 2.14), were used as templates in sequencing reactions. Reaction mixture:  
 
4 µl Seq.mix (Amersham Bioscience) 
5 pmol. lib-3 primer, s 
DNA (10 ng DNA for per 100 bp DNA length) 
HPLC water up to 10 µl total volume. 
PCR condition: 
 
Step  Temperature (°C)  Time (sec)  Number of cycles 
1  95  20 
2  50  15 
3  60  60 
 
25 
Hold  4                                     
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PCR products were purified on AutoSeq G-50 columns (Amersham Pharmacia) and analyzed by 
MegaBACE sequencer.  
 
2.7  Preparation of Competent Bacterial Cells for Electroporation  
A primary culture of XL-1 blue was made in 50 ml LB medium, and incubated overnight at 37 
oC and 250 rpm. Then 1 L of pre-warmed LB medium was added and incubated until OD600 
reached 0.5 to 0.6. The bacterial cells were pelleted 3 times and resuspended with 250 ml ice-
cold water, 50 ml then 5 ml of 10% (v/v) glycerol. 50 µl aliquots of the bacteria were prepared, 
frozen in liquid nitrogen and stored at –70 
oC.  
 
2.8  Preparation of Heat-Shock Competent Bacterial Cells 
1  ml  overnight  culture  of  either  XL-1  or  BL-21  cells  was  diluted  in  50 ml  medium  A  and 
incubated at 37 
oC with shaking until OD600 reached 0.3 to 0.5. The cells were cooled down on 
ice for 10 min, then pelleted and resuspended in 0.5 ml ice-cold medium A. 2.5 ml ice-cold 
solution B was added and mixed gently. 100 µl aliquots were made and stored at -70 
oC after 
quick freezing in liquid nitrogen.  
 
Medium A 
LB medium supplemented with 10 mM MgSO4 and 0.2% (w/v) glucose, sterile filtered and 
stored at 4 °C. 
Solution B 
Glycerol (36%, w/v) 
24% (m/v) PEG (Polyethylene glycol. MW 7500) 
0.012 M MgSO4  
In LB medium . 
 
2.9  Transformation of DNA into E. coli Cells by Heat Shock  
1 µl of plasmid DNA or up to 10 µl of ligation mixture were added to an aliquot of competent 
cells and incubated on ice for about 10 minutes after gentle mixture by flicking. The competent 
cells were heat-shocked at 42 
oC for 60 s, then stored on ice for 2 min, followed by addition of 1                                 
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ml LB medium and incubation at 37 
oC for 1 hr on a shaker. The cells were pelleted and plated 
onto LB agar plates with appropriate antibiotics and incubated at 37 
oC overnight.   
 
Commonly used antibiotics 
Antibiotics  Stock concentration (mg/ml)  Storage  Working dilution 
Ampicillin  100  -20 °C  1:1000 
kanamycin  50  -20 °C  1:1000 
Tetracycline.HCl*  50  -20 °C  1:1000 
 
* Tetracycline needs to be stored in the dark. 
 
2.10  Protein Expression in E. coli Cells 
BL21 cells transformed with plasmids were spread on a LB plate with appropriate antibiotics. 
One colony from the plate was diluted in 50 ml LB broth with antibiotics in a 2.5 L flask and 
incubated on a shaker (250 rpm) at 37 
oC overnight. 1 L pre-warmed fresh LB with antibiotics 
was added and the cells cultured for additional 3-4 hr until the OD600 reached 0.6, then protein 
expression was induced by adding IPTG (isopropyl-β-thiogalactopyranoside, final concentration: 
0.3 mM) and incubation for 4 hr. The cells were harvested and the pellet was frozen at -70 
oC. 
The frozen  cells  were  resuspended  in  25  ml  cold  PBS  supplemented  with  protease  inhibitor 
mixture CompleteTM (Roche Diagnostics), and lysed by French Press at 500 psi, 4-6 times until 
the  suspension  became  transparent.  After  centrifugation  of  the  lysate  with  a  Beckman 
Ultracentrifuge at 100,000 g for 45 min at 4 
oC, the supernatant was aliquoted and frozen at -70 
oC. 
 
2.11  Transfection of DNA into HEK 293 Cells 
HEK 293 cells were maintained in MEM medium supplemented with 10 % (v/v) FCS, 2mM 
glutamine and 50 units/ml penicillin/streptomycin. For transfection, 80% confluent HEK 293 
cells were split by 1:3. One day later, the medium was exchanged with 10 ml fresh medium per 
10-cm dish. Another 2 hr later, the transfection mixture was prepared by mixing 300 µl of 1 M 
CaCl2 with 900 µl H2O containing 5 µg of each DNA, then with 1.2 ml of 2× BBS (see below), 
mixing carefully, and incubating 3 min at RT. The mixture was slowly added to the culture                                 
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medium. 1 min later, the culture dish was swirled gently and put back into the 37°C, 5% CO2 
incubator for 18 to 24 hr, then the medium was exchanged again. The cells were incubated for 
another 18 to 24 hr before harvesting. 
 
2×BBS (BES-buffered solution) 
50 mM N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) 
280 mM NaCl 
1.5 mM Na2HPO4.7H2O 
pH was adjusted to 6.95 with 1 M NaOH 
 
2.12  Sumo-1 Conjugation in vivo 
The  following  DNAs  were  co-transfected  in  different  combinations  into  HEK293  cells  as 
described above:  
pEGFP-mGluR8a-C 
pEGFP-C2 
pECFP-sumo-1 
pcDNA3-His6-aos1 
pEYFP-ube2a 
pEGFP-Pias1 
 
Two days after the transfection, cells were washed with PBS and harvested with 2x sample 
buffer supplemented with 20 mM N-ethylmaleimide, followed by boiling for 15 min at 95 
oC and 
analysis by Western blot. 
2x Sample buffer (for SDS-PAGE) 0.125 M Tris-Cl (pH 6.8) supplemented with 0.1% (w/v) 
SDS, 20% (v/v) glycerol, 0.2% (w/v) bromophenol blue and 4% (v/v) β-mercaptoethanol  
 
2.13  GST-Pulldown 
Proteins expressed in E. coli were prepared as described in 2.10. For expression of proteins in 
mammalian  cells,  combinations  of  plasmid  DNA  were  transfected  into  HEK  293  cells  as 
described in 2.11. Two days after transfection, the cells were harvested after briefly washing 
with PBS, followed by 2 hr solubilizing with 1% (v/v) Triton X-100 in PBS supplemented with                                 
  20   
protease  inhibitor  mixture.  After  centrifugation  for  45  min  at  45,000  g, the  supernatant  was 
aliquoted and frozen at –70 
oC.  
For GST pulldown, GST-fusion proteins were immobilized on glutathione-Sepharose 4B beads 
(Amersham Biosciences) by incubating 300 µl of bacterial lysate with 25 µl beads in 700 µl 
incubation buffer for 1 hr with gentle rotation at 4°C, followed by three washings with wash 
buffer. 40-120 µl of bacterial extract of an MBP fusion protein or 40 µl HEK cell extract of a 
GFP fusion protein were added and incubated with the beads for 2 hr and followed by washing 
as explained above. The protein binding beads were resuspended in 30-µl 2x SDS-PAGE sample 
buffer and boiled for 5 min. 
 
Wash buffer: PBS (0.01M phosphate buffered 0.15 M saline, pH 7.4) supplemented with 0.1% 
(v/v) Triton X-100, 2 mM EDTA, 2 mM EGTA and 2 mM dithiothreitol. 
Incubation buffer: Wash buffer supplemented with protease inhibitor mixture. 
 
2.14  Western Blot 
A 1.2 mm thick SDS-PAGE mini gel (Bio-Rad) was run at 15 mA constant current for the 
stacking gel and at 20 mA for the separating gel until the bromophenol blue tracking dye reached 
the bottom of the separating gel. The gel was electro-blotted at 10 V overnight to transfer the 
proteins to a nitrocellulose membrane (Schleicher & Schuell). The proteins on the membrane 
were stained with Ponceau S solution for 5 min followed by washing with water until protein 
bands appeared. The protein standards (Sigma) were marked. The membrane was incubated in 
blocking buffer for 1 hr on a shaker. After washing briefly with PBST, the primary antibody 
diluted in blocking buffer was applied, and incubated at 4 
oC overnight, followed by 3 times 
washing  with  PBST.  The  secondary  antibody  diluted  in  blocking  buffer  was  applied,  and 
incubated at RT for 1 hr; followed by 3 times washing with PBST. The blot was incubated with a 
mixture from the SuperSignal West Pico Chemiluminescent Substrate Kit (PIERCE, Rockford, 
IL,  USA),  detected  by  X-ray  films,  which  were  developed  with  Kodak  X-OMAT  2000 
processor. 
 
PBST 0,05% (v/v) Tween20 in 0.01M PB-0.15M saline. 
Ponceau S 2% Ponceau S (w/v) and 3% (w/v) trichloroacetic acid disolved in H2O.                                 
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Blocking buffer PBS supplemented with 5% (w/v) milk powder (nonfat) and 5% (w/v) BSA 
Primary antibodies 
Antibody  Company  Dilution used 
GFP (rabbit)  Clontech  1:200 
MBP (rabbit)  New England Biolab  1:10,000 
mGluR8a (Guinea Pig)  Gift from Dr. 
Shigemoto 
1:5000 
Pias1 (rabbit)  Santa Cruz  1:50 
Sentrin 1 (/SUMO-1, mouse)  Zytomed  1:200 
 
Secondary antibodies 
 
Antibody  Company  Dilution used 
HRP-goat-anti-rabbit  Dianova  1:10,000 
HRP-goat-anti-mouse  Dianova  1:10,000 
HRP-goat-anti Guinea Pig  Biomol  1:10,000 
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3  RESULTS 
 
3.1  Yeast Two-Hybrid Screens with the Tail Regions of mGluR8a and mGluR8b  
To identify proteins interacting with the cytoplasmic C-terminal tail regions of mGluR8a and 
mGluR8b, two-hybrid screens were performed using the DupLexA yeast two-hybrid system. The 
yeast two-hybrid system has been proven to be a powerful method for identifying protein-protein 
interactions. The general principle of the LexA yeast two-hybrid system is shown in Figure 2A. 
Two proteins (X and Y) under test are fused separately with either a bacterial DNA-binding 
domain LexA, and the fusion construct is thus called the bait, or a yeast activation domain B42, 
and the fusion construct is called the prey. If X interacts with Y, the two fusion proteins will 
form a chimeric regulatory factor to activate reporter gene expression. In case of the mGluR8a/b 
screens (Figure 2B), the C-terminal tails of the receptor were fused with LexA separately and 
used  as  baits.  A  rat  brain  cDNA library  fused with  B42  was  used  as  the  pool  of  preys  for 
screening. The DupLexA yeast two-hybrid system has two reporter genes: LacZ & LEU2. Both 
reporter genes are under the control of multiple LexA operators, but with different promoters: 
LacZ is under the control of minimal TATA region of the yeast GAL1 promotor, and LEU2 is 
under the control of the yeast LEU2 promotor. The multiple LexA operators contribute to the 
sensitivity and discrimination power of the two-hybrid assay. The different promoters help to 
eliminate some false positives and to confirm positive two-hybrid interactions. As expression of 
both  B42  and LexA  fusion  proteins  is  under the  control  of  GAL1  promoter, the  whole  test 
system is under the control of the carbon source in the medium. Hence expression is induced in 
Gal/Raf medium, but inhibited in medium containing glucose. 
 
3.1.1  Test of the Baits’ Ability to Enter the Nucleus and Bind LexA Operator 
Before  applying  the  baits  to  yeast  two-hybrid  screening,  they  had  to  be  tested  for  nuclear 
localization and autoactivation of both reporter genes. Firstly, I examined whether they entered 
the nucleus and bound to the LexA operators. Both baits underwent separate cotransformation 
with pJK101 into EGY48. Single transformation of pJK101 was also performed as control. The 
plasmid pJK101 contains a LacZ reporter gene, whose expression is driven by the yeast GAL1 
promoter.   Two  LexA  operators have been placed  between the  GAL1 promoter and the  LacZ  
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Figure  2.  A.  The  principle  of  the  LexA  yeast  two-hybrid  system.  Modified  from  CLONTECH  
MATCHMAKER LexA Two-Hybrid System-User Manual. The interaction between two proteins (X and Y) is 
tested in this system. X is fused with an E. coli DNA binding domain LexA and called the bait. Y is fused with 
a yeast activation domain B42 and called the prey. If X interacts with Y, a LexA-X-Y-B24 chimeric complex 
will form, which binds to the LexA operator and activates the reporter gene expression. B. The components of 
DupLexA yeast two-hybrid system used for mGluR8a-C screen. Bait,  prey and  LacZ reporter plasmids with 
different selection markers are cotransformed into EGY48 cells that contain another reporter gene, LEU2. The 
bait plasmid expresses LexA- mGluR8a-C. The prey plasmids express B42 fused with proteins encoded by a 
cDNA  library.  Expression  of  both  B42  and  LexA  fusion  proteins  is  under  the  control  of  yeast  GAL1 
promoters, therefore is controlled by glucose/galactose in the medium. LEU2 and LacZ genes have multiple 
LexA operators and will be activated if any library protein interacts with mGluR8a-C in the same yeast cell, 
thus the yeast cell can grow into a blue clone on a Gall/Raf/-HUTW/X-Gal plate. 
Gal/Raf 
Gal/Raf  B
4
2 
A 
B 
prey                                
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gene.  LexA  fusion  proteins  will  bind  to  these  operators  and  delay  the  GAL1-  driven  LacZ 
expression.  
The yeast clones were transferred onto a filter and lysed by freezing-thawing, X-Gal solution 
was then applied onto the filter to measure the LacZ activity in these yeast cells. 10 min later, all 
clones started to turn blue, but the group transformed with only pJK101 was stronger than those 
cotransformed with pJK101 and the baits. 30 min later, the difference was more pronounced, and 
lasted at least for 3 hours. This result proved that the LexA-mGluR8a-C and LexA-mGluR8b-C 
fusion proteins were able to enter the nucleus and to bind to the LexA operators. 
 
3.1.2  Test for Autoactivation of the Bait Constructs 
In the LexA yeast two-hybrid system, the integrated LEU2 nutritional reporter gene allows the 
otherwise Leu– auxotrophic host cell EGY48 to grow on SD induction medium lacking leucine 
when transformed with plasmids encoding interacting hybrid proteins. When lacZ transcription is 
activated  in  EGY48[pSH18-34],  the  cells  produce  β-galactosidase,  whose  activity  can  be 
visually  monitored.  It  is  therefore  important  that  the  bait  constructs  do  not  show  any 
autoactivation  of  the  reporter  genes.  Both  bait  constructs  pGilda-mGluR8a-C  and  pGilda-
mGluR8b-C had already been tested in our laboratory for lack of transactivation of the LacZ 
gene in the presence of galactose. A small-scale transformation was performed here to examine 
whether these baits were able to activate the other reporter gene, LEU2. 
The bait and reporter plasmids were cotransformed into EGY48, and the cells were plated onto 
Glc/-UH plates to allow all cotransformed cells to grow. Four days after transformation, one 
clone from each group was picked up, diluted with water and plated on both SD/Gal/Raf/-UHL 
and SD/Gal/Raf/-UH 10-cm plates. Five days later, clone numbers were counted as listed in 
Table 4. 
All yeast cells with the bait and reporter plasmids grew on SD/Gal/Raf/-UH plates, thus the 
number  of  clones  growing  on  these  plates  was  used  to  calculate  the  concentration  of  yeast 
suspension plated. As no prey plasmid was introduced, the growth of yeast cells on SD/Gal/Raf/-
UHL was considered to be the result of autoactivation of the reporter gene LEU2 by the baits. 
According to Table 4, we obtained 76 yeast clones out of 7.85 x 10
6 for mGluR8a-C, and 100 
yeast clones out of 2.4 x 10
7 for mGluR8a-C growing due to autoactivation (Table 4). This 
suggests there would be about 2,000-5000 clones with autoactivation in a screen under such                                
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selective conditions, in case approx. 5 x10
8 yeast cells would be screened as usual. This high 
value of autoactivation found with both baits is not acceptable for standard screening procedures. 
One possibility to suppress autoactivation is to decrease the concentration of galactose in the 
medium. After testing the growth of transformed yeast cells on SD/Gal/Raf/-UHL plates with 
different concentrations of galactose, a concentration of 1.5% was found to be the optimum.  
 
 
 
3.1.3  General Description of the Screening Procedure 
The procedure of the two-hybrid screens is shown in Figure 3. 6.3 x10
8 yeast cells
 were screened 
for mGluR8a and 8.4x10
8 for mGluR8b. 1,385 and 934 clones, respectively, were found to be 
positive by Leu- auxotrophy and expression of LacZ. PCR reactions were performed to amplify 
the insert cDNAs in the prey plasmids. Products with only single bands on agarose gels were 
selected  and  grouped  by  size,  followed  by  Hae  III  digestion.  The  digestion  patterns  were 
compared on 1% agarose gels. Samples of identical size and restriction pattern were assigned to 
the same group. One to five purified PCR products of each group were selected for sequencing. 
In total, about 100 PCR products of each screen were sequenced. 
Table 4. Clone numbers of cotransformants obtained with bait and reporter plasmids 
grown under permissive (*) and testing (**) conditions 
 
Baits  Plates  Primary 
suspension 
1:100  1:10,000  1:1,000,000 
SD/Gal/Raf/-UH*      785    mGluR8a-C 
SD/Gal/Raf/-UHL**  76       
SD/Gal/Raf/-UH*        24  mGluR8b-C 
SD/Gal/Raf/-UHL**  100       
 
EGY48 cells were cotransfected with reporter plasmids (URA3) and bait plasmids (HIS3) including 
either mGluR 8a-C or mGluR8b-C, and plated on Glc/-UH selective plates. One clone from each 
group was picked and plated on Gal/Raf plates as shown, with or without leucine in the medium. 
Only the plates with 20 and 1000 clones were counted and listed.  
* Permissive growth condition for the cotransformed cells. 
**Selective conditions for autoactivation of bait protein on reporter gene LEU2.                                
  26   
 
 
A  B 
C 
D 
E 
F 
Figure  3.  The  yeast  two-hybrid 
screening  procedure. 
A.  Positive  clones  obtained 
after screening. 
B.  Freezing-thawing 
treatment  of  yeast  cells 
with  liquid  nitrogen  and 
water.  
C.  Amplification of insertions 
by  PCR.  Only  samples 
yielding  single  bands  as 
revealed  by  agarose  gel 
electrophoresis  are 
selected  for  subsequent 
analysis. 
D.  List  of  the  PCR  products 
according to size. 
E.  Hae  III  digestion  patterns 
of  the  PCR  products. 
Samples  with  the  same 
frequent  pattern  were 
grouped together. 
F.  DNA  sequencing  of 
representive  PCR 
products.                                
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3.1.4  Results of the Yeast Two-Hybrid Screens 
After DNA sequencing, about 30 proteins were identified as interacting candidates (Table 5). All 
clones were in-frame with the B42 activation domain. Some of them, especially those identified 
most frequently, were fished in both the mGluR8a-C and mGluR8b-C screens. There were also 
many candidates interacting with only one of the baits; however, most of these interactions were 
found only once.  
 
All of the predicted interacting proteins could be divided into 3 classes. The first comprises 
sumoylation proteins, including the first three most frequently found candidates: Pias1, Piasxβ 
Baits  Candidate interacting protein cDNA homologues  Genebank 
No. 
Clones 
8a/b  Protein inhibitor of activated STAT 1 /Pias1  62653796  12/13 
8a/b  Msx-interacting-zinc finger (Miz1)/Piasx   16758049  12/9 
8a/b  Ubiquitin conjugating enzyme E2I (Ube2i)/ube2a  4079642  9/3 
8a/b  Polymyositis/scleroderma autoantigen 1/Pmscl1*  8132102  3/6 
8a/b  Homeodomain-interacting protein kinase 3/Hipk3  13929113  2/2 
8a  Neurofilament protein, middle polypeptide  8393822  6 
8a  CDK103 mRNA  5931735  3 
8b  Anaphase-promoting complex 2 (LOC227617)  62644719  2 
8b  Ubiquitin-like 1 (Ubl1)/sumo1  57528278  2 
8a/b  ADP-ribosylation factor-like 2 (Arl2) *  66911464  1/1 
8a  cAMP-dependent protein kinase inhibitor protein mRNA /PKAi  6981393  1 
8a  Creatine kinase-B (CKB) mRNA, 3' end  56388798  1 
8b  Fas-associated factor 1/Faf1  15284035  1 
8a  Guanine nucleotide binding protein, beta 2/G 2  41351300  1 
8a  Mitochondrial nd1 gene for NADH dehydrogenase subunit  1  13472  1 
8a  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex  33563265  1 
8b  Ornithine aminotransferase (Oat)  40254768  1 
8b  Protein inhibitor of activated STAT   /Pias   62651709  1 
8a  RIKEN cDNA 1810009N24 gene (1810009N24Rik)  62654507  1 
8a  RIKEN cDNA 2810028A01 gene (2810028A01Rik)  62078862  1 
8a  Chemokine ligand  62648835  1 
8a  TATA element modulatory factor 1  63545828  1 
8b  Thymosin beta-4 (Tmsb4x)  13592118  1 
8a  Zinc finger protein of the cerebellum 1 (Zic1)  70778755  1 
 
Yeast two-hybrid screens were performed with C-terminal tails of mGluR8a and mGluR8b as the baits. 
The insertions of prey cDNA from positive clones were amplified by PCR and sequenced. The cDNA 
sequences were compared with sequence database of NCBI BLAST. 
*Not confirmed by yeast mating assay. 
Table 5. List of candidate interacting proteins of mGluR8a/b-C 
Found in yeast two-hybrid screens                                
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and  ube2a,  together  with  two  proteins  found  only  for  mGluR8b:  sumo-1  and  Piasγ.  These 
proteins play different roles in the sumoylation pathway as detailed in Figure 1 of the Appendix 
II. Sumo-1 is the modifier, ube2a is the conjugating enzyme (E2), and Pias1, Piasxβ and Piasγ 
are ligating enzymes (E3). The second class of identified proteins are related to apoptosis: Hipk3 
and Fas-related protein. They will be discussed later. The third class includes all remaining gene 
products. 
 
3.2  Yeast Mating Confirms that Sumoylation Proteins Interact with mGluR8a/b 
After the two-hybrid screen, a yeast mating assay was performed to confirm the interactions 
between the candidate proteins and the mGluR8 bait sequences. The general idea of yeast mating 
is that two complementary yeast cells, carrying different plasmids introduced in the yeast two-
hybrid screen, mate together to form a diploid yeast cell. The interactions between the bait and 
the prey proteins then again can be tested in the diploid cell. Taking advantage of the positive 
EGY48 clones identified so far, yeast mating has been proven to be an efficient procedure to 
quickly eliminate false positive candidates. It is also an effective method to test whether a prey 
protein  fished  with  one  bait  also interacts  with another  one.  The  procedure  is  schematically 
depicted in Figure 4. 
 
Figure  4.  Principle  of  yeast 
mating.  Two  complementary 
yeast  strains  were  used: 
EGY48  carried  prey  plasmids 
and  both  LEU2  and  LacZ 
reporter  genes.  RFY206 
contained  only  bait  plasmids. 
After  mating,  two 
complementary  yeasts  were 
fused and formed a diploid cell, 
onto  which  the  same  test 
system  as  shown  in  Figure  3 
was employed.                                
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3.2.1  Segregation of Bait Plasmids from Yeast and Test for Autoactivation of the Prey 
Proteins 
To prepare cells for mating, bait plasmids were segregated from the cotransformant EGY48, 
leaving the reporter and the prey plasmids in the cells according to the principle shown in Figure 
5. Eleven clones of cotransformants of nine candidate cDNAs were treated in this way (Table 7). 
In addition, essential tests to check whether the prey proteins alone were able to activate the 
reporter gene(s) were performed. These clones were plated onto Gal/Raf/-UW/X-Gal. None of 
the nine candidate plasmids examined activated the LacZ reporter gene. Therefore the yeast cells 
containing these plasmids were used for the yeast mating assay. 
 
Figure 5. Segregation of bait plasmids from the yeast cells and test of the autoactivation potential of the 
prey proteins. A. Cells from a single clone were cultured in YPD+Glc medium. Some of the growing 
cells lost one or more of the three plasmids. The numbers of plasmids left in the cells are indicated. B. 
The yeast cells were spread onto a SD/Glc/-UW plate, only cells still containing both p18-34 and pJG4-
5-X grew. C. The same clones were spread on two different plates with or without His. Two (e.g. A2 and 
C1 ) clones did not grow without His because they had lost pGilda-8a. D. Clones A2 and C1 were plated 
onto SD/Gal/Raf/-UW/X-Gal. None of them were blue, means the LacZ gene was not activated by the 
prey protein, hence they were verified further.                                
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3.2.2  Yeast Mating Results 
RFY206 cells (MATa) carrying either empty bait plasmid pGilda, or bait plasmid inserted with 
either  mGluR8a-C  or  mGluR8b-C,  were  incubated  together  with  EGY48  cells  (MATα)  that 
carried only one of the prey plasmids and the reporter plasmid. Both RFY206 and EGY48 are 
haploid, and they are of complementary mating type. RFY206 cells carry all selective markers 
for auxotrophy EGY48 cells have. Between these two complementary haploid cells yeast mating 
occurred:  they  fused  and  incorporated  into  a  single  diploid  cell.  The  diploid  cells  share  all 
common auxotrophy selective markers with both haploid cells, and thus can be tested in the same 
way as in the yeast two-hybrid screen. 
When  testing  the  diploid  cells  for  Leu-  auxotrophy  and  LacZ  expression,  all  of  the  cells 
expressing the five sumoylation proteins and some of the other candidates were found to be 
positive, and hence considered to be interaction partners of both mGluR8a and mGluR8b (table 
7). Notably, Piasγ and sumo-1 that were found only with mGluR8b-C in the two-hybrid screen 
also gave positive signals with mGluR8a-C. Two other fusion proteins (Pmscl and arf1) failed to 
interact  with  mGluR8a-C  and/or  mGluR8b-C  in  the  yeast  mating  assay;  therefore  they  were 
deleted from the candidate list. As all sumoylation proteins were confirmed by yeast mating, I 
focussed on these proteins. 
pGilda fused with tail  of 
 
               
            Bait 
  Target  mGluR2 
 
mGluR3 
 
mGluR4 
 
mGluR6 
 
mGluR7a 
 
mGluR8a 
 
(empty) 
 
  pJG4-5 
(Neg control) 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
pJG4-5-Pias  1 
(C-terminal) 
 
 
- 
 
- 
 
+ 
 
+ 
 
++ 
 
+++ 
 
- 
 
Table 7. Pias1 interacts with all group III, but not group II mGluRs in 
the yeast two-hybrid. 
Yeast cells with reporter genes and prey plamids containing a C-terminal domain of Pias1 
were  transformed with pGilda bait  plasmids  fused with C-terminal  tails of  the different  
group II and III mGluRs. The cotransformants were selected on Gal/Raf/-UHWL plates. 
-, no clones observed on the plates. 
Positive clones were estimated qualitatively as: 
+, faint blue; ++, medium blue; +++, strong blue.                                
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3.3  Pias1 is the Primary Interaction Partner for mGluR8 
For  further  confirmation  of  the  results  of  the  yeast  two-hybrid  screen,  GST-pulldown 
experiments were performed. For this purpose, target plasmids were isolated from the yeast cells 
in order to subclone the insert into expression vectors and to generate fusion proteins. 
 
3.3.1  Isolation of Prey Plasmids from Yeast Cells 
The prey plasmids containing the cDNAs of the candidate interacting proteins were isolated from 
yeast according to the procedure illustrated in Figure 6. This is actually a new protocol taking 
advantage of the LacZ gene present in the reporter plasmids.  Briefly, plasmid DNA was isolated  
 
from yeast and transformed into XL-1 bacterial cells. The bacteria were plated onto LB-Amp-X-
Gal plates. Some bacterial clones were blue because they contained the reporter plasmid pSH18-
34. pSH18-34 contains a LacZ gene that can be activated by the bacterial LexA full transcription 
Figure 6. Isolation of target plasmids from yeast cells. A. A single clone was cultured in SD/Glc/-W 
medium. Some of the growing yeast cells lost some of their plasmids, but pJG4-5-X got enriched. B. 
Plasmid DNA was isolated from yeast cells and transformed into XL-1, which were plated onto LB-
Amp/X-Gal plates.  C. Some bacterial clones were blue, which suggested that they contained p18-34 
with  the  LacZ  reporter  gene.  Small  scale  cultures  of  WHITE  clones  were  made,  followed  by 
preparation of plasmid DNA, then digestion with ECoRI/XhoI. D. Gel electrophoresis of the digested 
samples. Clones 1, 2, 3, 5, 7, 9, 11, 12 contained only the target plasmid; clone 4, 6, 8 contained both 
the bait and the target plasmids.   
3    
3 
1  2 
1 
3 
3 
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regulator protein. After isolating plasmid DNAs from the bacterial clones that were not blue and 
checking them by restriction analysis, all sumoylation related target plasmids were isolated, and 
their identity was confirmed by DNA sequencing. 
 
3.3.2  Construction and Expression of MBP Fusion Proteins  
Constructs for generating the MBP fusion proteins MBP-ube2a and MBP-Piasγ were made by 
subcloning inserts from the corresponding target plasmids into pMal-c2 (Figure 7). Successful 
expression  of  the  recombinant  proteins  was  checked  by  Western  blotting  with  anti-MBP 
antibody (Figure 8, input lanes). Fusion constructs of all other clones are listed in Appendix I.  
 
Figure 7. Strategy used for generating pMAL-c2-ube2a (A) and pMAL-c2-PIASγ (B). The full-length 
fragment of ube2a and the C-terminal fragment of PIASγ were cut from pJG4-5-ube2a and pJG4-5-
PIASγ, respectively, using EcoRI and XhoI sites, and inserted into pMAL-c2 between EcoRI and SalI 
sites.  
EcoR 1     
       Sal I 
pJG4-5-ube2a 
  
pMAL-c2 
pMAL-c2-ube2a 
EcoR 1 
Xho I 
pJG4-5- PIASγ 
pMAL-c2-PIASγ(C157) 
EcoR 1 
Xho I                                
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3.3.3  GST Pulldown Assay 
E.coli  expressed  GST-mGluR8a-C  and  mGluR8b-C  fusion  proteins  were  immobilized  on 
glutathione beads. Candidate interacting proteins, ube2a, Pias1 and Piasγ, were also expressed in 
bacteria as MBP-fusion proteins and incubated with the beads, followed by washing, elution with 
SDS sample buffer and analysis by SDS-PAGE and Western blotting with an antibody against 
MBP. Figure 8 shows that MBP-Pias1 could be affinity-purified with GST-mGluR8b-C bound to 
glutathione-Sepherose beads and, to a lesser extent, with immobilized GST-mGluR8a-C, but not 
GST alone. A comparatively weak interaction was also detected for the MBP fusion of the C-
terminal region of Piasγ, which similarly bound to both mGluR8-C isoforms. GST alone failed to 
bind MBP and all MBP-fusion proteins tested. MBP-ube2a did not exhibit detectable binding to 
any of the GST-mGluR8-C-termini under the conditions used (Figure 8).  
 
GST pulldown experiments were also performed using mammalian expressed proteins. cDNA 
constructs  encoding  full-length  Pias1,  ube2a  and  sumo-1  were  generated  according  to  the 
strategies  listed  in  Appendix  I.  CFP-sumo-1,  YFP-ube2a  and  GFP-Pias1  were  all  efficiently 
Figure 8. GST-mGluR8-C fusion proteins interact with MBP-Pias1. GST, GST-mGluR8a-C 
and GST-mGluR8b-C were immobilized on Glutathione-Sepharose beads and incubated with 
50 µl of extracts from bacteria expressing MBP-fusion proteins of fulllength ube2a Pias1 and a 
C-terminal 157 AA fragment of Piasγ (input lanes show protein expression in 20 µl of bacterial 
extracts). After washing the beads repeatedly by incubation buffer, bound proteins were eluted 
with SDS-sample buffer, and analyzed by SDS-PAGE followed by Western blotting with an 
anti-MBP antibody. Note that MBP-Pias1 was retained on GST-mGluR8b-C and, to a lesser 
extent, on GST-mGluR8a-C, while GST failed to bind MBP-fusion proteins. Weak binding 
was also seen with MBP-Piasγ on both mGluR-Cs. 
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expressed in HEK 293 cells, and Triton-X 100 extracts of the transfected cells were used in 
binding assays (Figure 9). An interaction could be confirmed for mGluR8a-C and GFP-Pias1, 
while only very little or no YFP-ube2a was recovered in the bound protein fraction. GFP alone 
did not bind to GST-mGluR8a-C. In contrast to the results obtained in the original yeast-mating 
assay, GST-mGluR8a failed to bind CFP-sumo-1 (approx. molecular weight 40 kDa) under these 
assay conditions but enriched two high molecular weight (≥ 90 kDa) sumo-conjugated proteins 
from the HEK cell lysate. The identities of these proteins are unknown, but an unbiased mass-
spectrometry  based  analysis  of  sumo-conjugated  HEK  cell  proteins  has  identified  several 
candidates in the respective molecular weight range (Zhao et al., 2004).  
 
Taken together, these GST pulldown results prove that, of the sumoylation proteins found, Pias1 
is the most robust binding partner of mGluR8. 
 
Figure 9: GST-mGluR8a-C interacts with GFP-Pias1, but not YFP-ube2a and CFP-sumo-1. Ube2a, 
Pias1 and sumo-1 tagged with different GFP variants were expressed in HEK 293 cells (input: 10 µl 
of HEK cell extracts; left panel). 50 µl Triton-X100 extracts of the transfected cells were incubated 
with GST or GST-mGluR8a-C, respectively (right panel). After the GST pull-down procedure, bound 
proteins  were  eluted  by  SDS  sample  buffer,  separated  by  SDS-PAGE  electrophoresis,  and 
immunoreactive bands were detected by Western blotting with an anti-GFP antibody. Note that GFP-
Pias1 binds to GST-mGluR8a-C but not to GST. Only a very weak interaction is detected with YFP-
ube2a.  Asterisks  mark  high  molecular  weight  bands  of  unknown  identity  that  were  bound  from 
extracts expressing CFP-sumo-1. Note that free sumo-1 was not recovered.                                
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3.4  Pias1 Interacts with All Group III mGluRs 
 
To examine whether binding of Pias1 is shared by all presynaptic members of the mGluR family 
(including group II and group III receptors), binary yeast two-hybrid assays were performed with 
Pias1 and all group II/III mGluRs. Cells of a positive clone from the two-hybrid screen, which 
Figure 10. Pias1 interacts with all group III, but not group II, mGluRs.  
A:  Alignment  of  rat  group  II  and  group  III  mGluR-C-termini  starting  from  the  predicted  end  of 
transmembrane domain VII. The first three  lysines of all  group III mGluR (mGluR4, 6, 7  and 8) C-
terminal tails are located in the highly conserved 5’ coding region which binds both G-protein βγ and 
calmodulin. In  the more variable C-terminal region, additional  lysines are found, some of which are 
conserved among isoforms. Bold letters: Sites homologous to the consensus sumoylation motif YKXE. 
Note that group II mGluRs (mGluR2 and 3, bottom) only contain a single conserved lysine in position +4 
after the predicted end of the last transmembrane domain. 
B. Mammalian expressed GFP-Pias1 interacts with GST fusion proteins of all group III mGluR C termini. 
GFP-Pias1 was expressed in HEK293 cells, and an aliquot (10 µl) of the cell lysate separated in the left 
lane.  Pull-down  assays  with  100  µl  of  HEK  lysate  on  GST,  or  GST-mGluR-Cs  as  indicated,  were 
performed as described under “Experimental Procedures.” Bound protein was detected after SDS-PAGE 
by Western blotting with an anti-GFP antibody. Note that GFP-Pias1 binds to all GST-mGluR-C termini 
but not to GST. Amounts of immobilized GST fusion protein were similar for all fusion proteins, as 
indicated by Western blotting with anti-GST (data not shown), except for GST-mGluR8a for which only 
25% of the average protein level was bound. 
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encoded the C-terminal domain of Pias1 and had been segregated from the bait plasmids, were 
transformed with bait plasmids containing the C-terminal tails of different mGluRs and tested for 
reporter gene activation. In these assays, mGluR8a-C showed the strongest interaction, followed 
by mGluR7a-C and then mGluR6-C / mGluR4-C (Figure 10 A). In contrast, neither mGluR2-C 
nor mGluR3-C interacted with Pias1. I also subcloned the full-length mouse Pias1 cDNA into 
the target plasmid and tested two-hybrid interactions in yeast cells using the same protocol. All 
cotransformants grew under the permissive (SD/Glc/–UHW), but none of them under selective 
(SD/Gal/Raf/–UHWL/X-Gal) conditions. As Pias1 contains a SAP domain in the N-terminal 
region  that  binds  to  A/T  rich  DNA  sequences,  it  is  possible  that  full-length  Pias1  binds  to 
exposed regions of yeast nuclear DNA, thereby loosing its ability to bind to the bait that is 
located at the LexA operator. Indeed, no interaction was observed in our experiments between 
the full-length Pias1 and C-terminus of any mGluR tested. 
Next, the interactions between Pias1 and all group III mGluRs were examined in GST pulldown 
experiments,  using  mammalian  cell  generated  GFP-Pias1  and  the  respective  GST-fused  C-
terminal tail of the mGluRs (Figure 10 B). While GST failed to bind GFP-Pias1 and conversely 
GFP  did  not  interact  with  GST-mGluR7a-C,  all  group  III  mGluR  C-termini  showed  some 
interaction. The strongest binding was detected with mGluR7a-C, mGluR4-C and mGluR6-C. 
The weak band recovered with GST-mGluR8a could be attributed to substantially less GST-
fusion protein being retained on the agarose beads (shown in Figure 11). In conclusion, all group 
III mGluR-C-terminal tails were able to bind GFP-Pias1. 
 
3.5  Mapping of the Pias1 Binding Domain of mGluR7a-C and mGluR8a-C 
To determine which domains of mGluR7a-C and mGluR8a-C interact with Pias1, the binding of 
mammalian  expressed  CFP-Pias1  to  respective  truncated  GST-fusion  proteins  was  tested.  A 
schematic drawing of the truncation mutants used is shown in Figure 11A. The mGluR7a-C 
truncation constructs did not overlap while those for mGluR8a-C overlapped by three amino 
acids. Also, the positions of the truncations were different in the respective C-terminal tails: for 
mGluR7a-C, GST-mGluR7a-N38 ends, and GST-mGluR7a-C27 starts, just before the conserved 
Lys889. For mGluR8a-C, GST-mGluR8a-N24 only included the proximal signal transduction 
domain with the G-protein βγ and Ca
2+/calmodulin binding sites (El Far et al., 2001), while GST- 
mGluR8a-C44  contained all conserved  lysines outside  of this signalling domain  including the                                 
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Figure 11. Mapping of the Pias1 binding region of mGluR7a-C and mGluR8a-C. 
A: mGluR7a-C and mGluR8a-C truncations and position of the consensus sumoylation motif. Schematic 
representation of mGluR7a and mGluR8a truncated fragments. The position of the consensus sumoylation 
motif is indicated in bold. Note that mGluR7a-N38, which binds GFP-Pias1, does not contain the consensus 
sumoylation site but overlaps with mGluR8a-C44 in the region proximal to the consensus motif. Single or 
multiple point mutations were introduced into the mGluR8a-C cDNA at all lysine codons that are conserved 
between mGluR8a and mGluR8b (K868R, K872R, K882R). 
B: Mapping of the Pias1 interaction site with mGluR8a-C. Upper panel: GST-fusion proteins of mGluR7a-
C and mGluR8a-C immobilized on glutathione-agarose beads were used in pull-down assays with 60 µl 
CFP-Pias1 expressed in HEK 293 cells. Western blots were stained with an anti-GFP-antibody. Pias1 failed 
to  bind  to  GST-mGluR7a-C27  and  GST-mGluR8a-N24,  whereas  the  K882R  (mGluR8a)  and  K889R 
(mGluR7a)  substitutions  within  the  consensus  sumoylation  motif  had  no  effect.  Lower  panel:  Relative 
amounts of GST or GST-fusion protein bound onto the beads were revealed by Ponceau protein staining. 
Note that low levels of immobilized GST-mGluR8a-C strongly bound large amounts of CFP-Pias1, while 
high levels of immobilized GST-mGluR8a-N24 failed to bind under identical conditions.                                
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putative  sumoylation  site  K882.  GST-fusion  protein  levels  were  normalized  and  tested 
semiquantitatively for amount retained on beads (Ponceau S stain on nitrocellulose membrane, 
Figure 11B, lower panel). Lower protein levels were seen particularly for GST-mGluR7a-N38, 
GST-mGluR7a-K889R,  GST-mGluR8a-C  and  mGluR8a-K882R.  Binding  of  CFP-Pias1  was 
found with GST-mGluR7a-N38 and mGluR8a-C44, while the complementary truncations GST-
mGluR7a-C27 and GST-mGluR8a-N24 failed to interact. In sequence alignments (Figures 10A 
and 11A), mGluR7a-N38 and mGluR8a-C44 overlap by 17 amino acids but are only identical in 
the last 6 residues preceding the consensus sumoylation motif (sequence DRPNGE; see amino 
acids 875-880 of mGluR8a). We therefore deduce that these residues are important for Pias1 
recruitment to group III mGluRs. 
 
3.6  In vivo Sumoylation of mGluR8a-C  
There are two ways to examine whether a protein can be sumoylated. The first option is to 
perform in vitro sumoylation assays. Here, the substrate protein is incubated with all components 
of the sumoylation machinery: sumo-1ΔC4 (matured sumo-1, with a deletion of the last four 
residues at C-terminus, exposing the Gly-Gly motif to be activated), aos1/uba2 (E1), ube2a (E2) 
and ATP, Mg
2+, with or without E3 (e.g. Pias1), at 37 
oC for 1-2 h. The resulting sumoylation 
products can then be detected on Western blots by their increased molecular weight, which is 
that of the substrate plus the molecular weight of sumo-1, in case of mono-sumoylation. This 
method is fast, but it needs complicated procedures for purifying all recombinant proteins, some 
of  which  are  not  well  expressed  in  bacteria.  In addition,  according  to  the  literature, in vitro 
assays do not faithfully reproduce physiological substrate selection mechanisms (Johnson, 2004). 
A better possibility is therefore to perform in vivo sumoylation assays. Here, the substrate protein 
is  cotransfected  with  sumo-1,  with  or  without  the  different  sumoylation  enzymes,  into 
mammanlian cells, which then are analysed for sumoylation products. This method needs highly 
specific  antibodies  to  visualize  the  sumoylated  products.  This  approach  was  selected  here 
because it allows visualization mGluR8a-C sumoylation in mammalian cells. 
3.6.1  in vivo Sumoylation of mGluR8a 
To demonstrate whether mGluR8a-C can be sumoylated, I performed in vivo sumoylation assays. 
GFP-mGluR8a-C and the  following  tagged  components of the  sumoylation  pathway were co- 
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a-C 
Figure 12. Preliminary analysis of GFP-mGluR8a-C sumoylation in vivo. Different combinations of GFP-
mGluR8a-C, CFP-sumo-1, His6-aos1, YFP-ube2a and GFP-Pias1 were transfected into HEK293 cells as 
indicated. Two days after transfection, the cells were washed and harvested with sample buffer containing 
SDS and NEM and processed to SDS-PAGE followed by Western blot using either anti-mGluR8a or anti-
sumo-1 antibodies.  
A. All samples were blotted with anti-mGluR8a antibody. A  major GFP-mGluR8a-C (38 kD) band (*) was 
detected in all lanes.  
Lane  1,  single  transfection  of  GFP-mGluR8a-C.    A  very  weak  extra  band  (arrow  head)  was  detected 
corresponding to the molecular weight (≈55 kD) of the GFP-mGluR8a-C (38 kD) + 1x sumo-1 (15 kD).  
Lane 2-5, cotransfection of GFP-mGluR8a-C, CFP-sumo-1 and the indicated sumoylation enzymes. Except 
for lane 4 from a transfection without YFP-ube2a, an additional band (arrow) was detected corresponded to 
the molecular weight (≈ 80 kD) of GFP-mGluR8a-C (38 kD) + 1x CFP-sumo-1 (50 kD).  
B.  Samples  were  from  triple  cotransfected  HEK393  cells.  The  additional  80  kD  band  (arrow)  can  be 
detected by both anti-mGluR8a and anti-sumo-1 antibodies.  
Left lane, the  80 kD band was detected by anti-mGluR8a antibody.  
Right lane, the same 80 kD band was also detected with anti-sumo-1 antibody on a parallel section of the 
same nitrocellulose strip as used for left lane. #, free CFP-sumo-1 detected by anti-sumo-1 antibody. 
 
His6-aos1 
 1           2          3          4          5 
Anti-mGluR8a-C 
A  B 
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expressed in HEK 293 cells in different combinations: CFP-sumo-1, one of E1-component His6-
aos1, YFP-ube2a (E2) and GFP-Pias1 (E3). After detergent extraction of the transfected cells in 
the  presence  of  protease  inhibitors,  the  extracts were  separated  by  SDS-PAGE  and  Western 
blotted  with  an  antibody  against  the  C-terminal  tail  of  mGluR8.  Under  these  conditions,  a 
significant fraction (about 1-5%) of the mGluR8a-C immunoreactivity present displayed a size 
shift to approx. 80 kDa, consistent with the addition of a single CFP-sumo-1 molecule (Figure 
12A). Parallel Western blotting showed that the 80-kDa band was also recognized by anti-sumo-
1 antibody (Figure 12B), thus confirming that this band indeed represented sumoylated GFP-
mGluR8a-C. It also suggested that mGluR8a-C was conjugated to a single sumo-1 molecule. 
Notably, in cells singly transfected with GFP-mGluR8a-C, a much weaker band at about 55 kD 
was also revealed by anti-mGluR8a antibody. This approximate molecular weight corresponds to 
the size of GFP-mGluR8a-C conjugated to endogenous sumo-1 (Figure 12A). The 80 kD sumo-1 
conjugation product disappeared when YFP-ube2a was omitted from the transfection mixture 
(lane 4 of Figure 12A). Apparently, ube2a is essential for conjugation. The addition of the aos1, 
a component of E1 enzyme, also enhanced the amount of sumoylation product as judged by 
semiquatitative Western blotting, whereas the addition of E3 had no effect. Analyzing the same 
Figure  13.  GFP  fusion  protein 
expression  upon  cotransfection.  GFP-
mGluR8a-C (lane A), GFP-mGluR8b-C 
(lane  B)  or  GFP  (lane  C)  were 
cotransfected  with  CFP-sumo-1,  E1-
components His6-aos1, YFP-ube2a (E2) 
and  GFP-Pias1  (E3).  The  cell  extracts 
were analysed by Western blotting with 
anti-GFP  antibody.  1#  indicates  GFP-
Pias1,  2#  YFP-ube2a  and  3#  GFP-
mGluR8a-C (lane A) or GFP-mGluR8b 
(lane  B).  4#  corresponds  to  free  GFP 
(lane  C).  The  remaining  bands  (in 
brackets)  probably  represent  other 
proteins conjugated to CFP-sumo-1.  
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Western blot with anti-GFP antibody showed that all GFP-fused proteins, including GFP-Pias1, 
were  well  expressed  (Figure  13);  this  excludes  potential  expression  problems.  Alternatively, 
Pias1 may be endogenously expressed in HEK293 cells. Western blot analysis of HEK293 cell 
extracts with anti-Pias1 antibody confirmed this idea (Figure 14). Clearly, there was endogenous 
Pias1 detectable in these cells, which may have been accounted for sumoylation of mGluR8a-C.  
Although the cotransfection of multiple DNAs mentioned above resulted in sumoylation, it was 
obvious that the expression level of each protein was low. After successive optimization, the 
triple cotransfection of sumo-1, mGluR8a-C and ube2a was found to yield the most reproducible 
results.  
In the various experiments performed in parallel, the results of the sumoylation assay showed 
considerable  variability.  This  may  have  been  caused  by  variability  in  the  activity  of 
isopeptidases. There are several proteins in mammalian cells that act as isopeptidase and cut 
sumo conjugations from its substrates. The isopeptidases are very active. I therefore examined 
whether the addition of N-ethylmaleimide (NEM), an isopeptidase inhibitor, might improve the 
results (Suzuki et al., 1999). Fresh aliquots of cells cotransfected with GFP-mGluR8a-C, CFP-
sumo-1  and  YFP-ube2a  were  solubilized  by  1%  Triton  X-100,  with  or  without  NEM.  After 
centrifugation, SDS-PAGE electrophoresis and Western blot with anti-mGluR8a antibody; only 
Figure 14. Endogenous expression of Pias1. A and B, an anti-Pias1 antibody was tested for specificity by 
Western blot of 10 µl Triton X-100 extracted recombinant proteins expressed in HEK 293 cells. GFP-
Pias1  (lane  B),  but  not  GFP  (lane  A),  was  detected.  In  the  sample  of  nucleus  fraction  (P1)  of 
untransfected HEK 293 cells, this antibody stained a band of about 70 kD (arrow), corresponding to the 
size of endogenous Pias1. 
GFP  GFP- 
Pias1 
A  B  C 
Endogenous 
Pias1                                
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the  pellet  treated  with  NEM  displayed  a  size  shift  of  the  mGluR8a-C  band  indicating 
sumoylation (Figure 15). This suggests that addition of NEM can inhibit desumoylation to some 
degree, but not completely, as the supernatant of NEM treated aliquot did not show a band of 
appropriate molecular weight. 
 
3.6.2  mGluR8a-C Is Sumoylated on Lysine 882 
Sumoylation involves the covalent conjugation of the C-terminal of sumo to the ε-NH2 group of 
a  Lys  side  chain  acceptor  site.  Many  but  not  all  of  the  acceptor  Lys  residue  lie  within  a 
consensus sequence ΦKXE/D, where Φ is a large hydrophobic amino acid; K, the Lys residue; 
X,  any  amino  acid;  E/D,  glutamate  or  aspartate.  Here,  Lys  substitutions  were  introduced  to 
identify  the  sumoylation  site.  This  method  is  commonly  used  to  confirm  sumoylation  of  a 
substrate  (Johnson,  2004).  Site  selection  was  based  on  two  criteria  obtained  from  the  GST 
pulldown assay: the acceptor Lys should be located within C44 of mGluR8a and conserved in 
both  mGluR8a  and  mGluR8b.  Accordingly,  three  Lys  residues  (K868,  K872,  K882)  were 
selected  as  candidate  sumoylation  sites.  Substitution  of  target  lysines  by  equally  charged 
arginines can be used to identify sumoylation motifs while corresponding alanine substitutions 
have been shown to result in reduced binding of E2 to substrate proteins, like the Ran GTPase-
activating protein (RanGAP1) (Sampson et al., 2001). Several KR mutations were made here 
Figure 15. NEM inhibits desumoylation. Fresh aliquots of cells cotransfected with GFP-mGluR8a-C, 
CFP-sumo-1 and YFP-ube2a were solubilized with 1% (v/v) Triton X-100 and protease inhibitors, with 
or without NEM for 2 hr. After  centrifugation, samples  were  analysed by SDS-PAGE  and Western 
blotting  with  anti-mGluR8a-C  antibody.  Note:  arrow  refers  to  the  sumoylated  GFP-mGluR8a  band. 
GFP-mGluR8a ran out of the gel. 
   pellet     supernatant      pellet      supernatant 
without NEM  with NEM                                
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including single, double and triple substitutions of the three Lys residues with Arg. All mutations 
were checked by DNA sequencing (Appendix I). 
 
The results of the sumoylation assays are shown in Figure 16. Modification of mGluR8a-C was 
abolished upon replacing Lys882 by arginine within the C-terminal tail (for positions of lysine 
substitutions, see Figure 11A). Triple arginine substitution including K882 also abolished sumo-
conjugation, while single or combined substitution of K868 and K872 did not interfere with this 
modification. Notably, sumo-conjugation did not occur on the neighbouring lysines K868 or 
K872  when  the  consensus  sumoylation  residue  K882  had  been  substituted.  Also,  K882R 
substitution or the triple mutation K868R/K872R/K882R did not lead to sumoylation of one of 
the remaining four lysines in the C-terminal tail of mGluR8a (Figure 16). Thus, in transfected 
Figure 16. mGluR8a-C is sumoylated on lysine 882. GFP-mGluR8a-C and the indicated CFP- and GFP- 
tagged  enzymes  of  the  sumoylation  pathway  were  co-expressed  in  HEK  293  cells.  48  h  after 
transfection, cells were harvested with SDS sample buffer supplemented with protease inhibitors and 20 
mM N-ethylmaleimide. The extracts were subjected to SDS-PAGE followed by Western blotting with 
an antibody directed  against the  mGluR8-CTD. In the presence but not absence of  enzymes of  the 
sumoylation  cascade,  a  size  shift  of  mGluR8a-C  to  ca.  80  kDa,  i.e.  the  approximate  size  of  the 
mGluR8a-C-CFP-sumo-1 conjugate, was observed. Single or combined arginine substitutions of K882 
abolished sumo-conjugation, while substitution of K868 and K872 had no effect.                                 
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cells sumoylation of mGluR8a-C occurs specifically at lysine 882 located within the conserved 
consensus sumoylation motif. Notably, arginine substitution of K882 in mGluR8a-C and of the 
homologous lysine K889 in mGluR7a-C did not affect binding of CFP-Pias1 in the GST pull-
down assay (Figure 11B). This further suggests that the interaction of Pias1 with mGluRs does 
not depend on an intact sumoylation consensus motif in the C-terminal tail. 
 
3.7  Yeast Two-Hybrid Screen with the C-terminal tail of mGluR4b 
During my PhD project, I also performed yeast two-hybrid screens with the C-terminal tail of 
mGluR4b. The yeast transformation had been performed by Dr. José Airas (see J. Airas, PhD 
thesis,  2001).  Basically,  the  intracellular  C-terminus  of  mGluR4b  had  been  subcloned  into 
pGilda and used as a bait to screen a rat brain cDNA library in the same way as for mGluR8a-C. 
The cotransformants were amplified, and aliquots were stored at –70 
oC. José had analysed a 
small  number  of  the  transformants,  and  found  cDNA  encoding  SGT  (Small  Glutamine-rich 
Tetratricopeptide-repeat-containing  protein)  and  PxF  (Peroxisomal  Farnesylated  protein)  as 
candidate interacting proteins. I joined the project for a more extensive screen. 
Candidate interacting proteins  Number of clones  Frequency 
(%) 
Confirmed by 
Yeast mating? 
SGT  70  59,8  + 
Proteasome, subunit K  11  9,4  + 
PLZF  8  6,8  + 
26 S proteasome, subunit  S5a  7  6,0  + 
PxF  4  3,4  + 
14-3-3  3  2,6  - 
Transthyretin  2  1,7  + 
Zeta crystalin  2  1,7  + 
Calmodulin  1  0,9  + 
DNA J-like  1  0,9  + 
Regulator of sterodogenic factor-1  1  0,9  + 
NapI-4  1  0,9  - 
Chromosome II, clone mCIT-268-p-2  1  0,9  - 
Testis cDNA  1  0,9  + 
Pancreas cDNA  1  0,9  - 
 
mGluR4b-C was used as the bait to screen a rat brain cDNA library in the yeast two-hybrid system. 
The candidate interacting proteins in this list were identified after DNA sequencing of insertions in 
prey constructs of positive clones . 
Table 7: Results of the yeast two-hybrid screen with mGluR4b-C 
mmfgfgfmmGluR4b-C                                
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1.5x10
8 yeast cells were screened, about 260 clones proven to be positive by Leu- auxotrophy 
and expression of LacZ. DNA sequencing revealed 15 cDNAs that might correspond to proteins 
that are candidate interactors for mGluR4b. 60% of the clones represented SGT. 15% of them 
belonged to proteasomal proteins, either subunit K or subunit S5a. 7% encoded a transcriptional 
repressor, promyelocytic leukemia zinc-finger protein (PLZF). 3.4% corresponded to PxF. The 
results are summarized in Table 7. 
To  confirm  the  results  of  the  yeast  two-hybrid screen,  yeast  mating  was  performed  with  all 
candidates found. For most of the candidates, again, positive results were obtained (see Table 7). 
Of these candidate clones, the SGT cDNA was most frequently isolated. SGT has originally been 
discovered because of its putative interaction with envelope proteins of two viruses (Callahan et 
al., 1998). It forms complexes with the synaptic proteins CSP (cysteine string protein) and Hsc70 
(heat-shock  protein  70  cognate),  which  functions  as  an  ATP-dependent  chaperone. 
Overexpression of SGT in cultured neurons inhibits neurotransmitter release (Tobaben et al., 
2001). Furthermore, SGT specifically coimmunoprecipitates with ß-amyloid peptide (Aß); and 
inhibition of SGT expression results in suppression of toxicity associated with A  ß expression 
(Fonte et al., 2002).  
Figure  17:  A  GST  pulldown  verified  the  interaction  between  mGluR4b  and  SGT.  GST-SGT  was 
immobilized on glutathione-agarose beads and incubated with bacterial extracts with MBP or MBP-
fusion of mGluR4b-C. After washing with incubation buffer, bound proteins were eluted with SDS-
sample buffer, and aliquots analyzed by SDS-PAGE followed by Western blotting with an anti-MBP 
antibody. The amount of samples loaded onto the left slots as control was about 20% of that used in the 
pulldown assay. 
  MBP         MBP-4b 
loaded proteins 
   MBP      MBP-4b 
GST-SGT                                
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Thus,  a  GST  pulldown  was  performed  to  examine  whether  overexpressed  recombinant SGT 
protein  would  bind  to  mGluR4b-C.  GST-SGT  was  immobilized  on  Glutathione  beads,  and 
incubated with MBP-mGluR4b-C or MBP. After washing, MBP-mGluR4b-C was retained on 
the beads as indicated by Western blotting using anti-MBP antibody, while MBP alone failed to 
bind the fusion protein (Figure 17). This is considered to be a specific interaction between SGT 
and mGluR4b-C. 
 
I also mapped the interaction domains of SGT and mGluR4b-C by yeast two-hybrid assays. As 
shown in Figure 18, SGT contains a TPR (Tetratricopeptide-repeat) domain between its N- and 
Figure 18: Interaction of SGT  and mGluR4b-C fragments in the yeast  two-hybrid assay. Different 
fragments were generated by PCR and inserted into the plasmids used for yeast-two-hybrid screening. 
A, SGT fragments were tested for interaction with full-length mGluR4b-C. B, mGluR4b tail fragments 
were tested with full-length SGT, respectively. 
+, interaction was detected in binary two-hybrid assay. 
-,  no interaction was detected in binary two-hybrid assay. 
A 
B 
Interaction 
+ 
- 
- 
- 
- 
+ 
+ 
- 
+ 
mGluR4b-C                                
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C- domains. Five cDNA fragments of SGT were generated by PCR, including three domains and 
two large fragments including the TPR domain and the N- and C-terminal regions, respectively 
(Figure  18). The  mGluR4b  tail  sequence  was  divided  into  2  fragments  according  to  second 
structure  prediction.  The  SGT  fragments  were  cloned  into  the  prey  vector  pJG4-5,  and  the 
mGluR4b-C  fragments  into  the  bait  vector  pGilda.  Yeast  two-hybrid  assays  were  performed 
using  full-length  SGT  and  the  mGluR4b-C  fragments,  or  full-length  mGluR4b-C  and  SGT 
fragments.  The  results  are  summarized  in  Figure  18  and  show  that  the  C-terminal  half  of 
mGluR4b-C interacted with SGT, and that both the TPR domain and the carboxyterminal region 
of SGT were required for this interaction. 
 
3.8  Database Search for Genomic mGluR4b Sequences 
When the experiments described above had been performed, a paper from Dr. Ferraguti’s lab 
was published that shed serious doubts on the existence of the splice variant mGluR4b (Corti et 
al., 2002). These authors had made numerous unsuccessful attempts to amplify by RT-PCR the 
sequence corresponding to the published C-terminus of mGluR4b from several rat brain areas 
(cerebellar cortex, olfactory bulb, neocortex and hippocampus). In contrast, amplification of the 
mGluR4a  sequence  was  always  achieved.  Apparently  other  laboratories  had  also  failed  to 
amplify mGluR4b. Hence, I performed a profound search of the human genome database but no 
evidence for the existence of the mGluR4b splice form was found. 
mGluR4b had been originally cloned from a rat cDNA library and published in 1997 (Thomsen 
et al., 1997). According to that report, the mGluR4b cDNA was identical to that of mGluR4a, but 
contained a 620-nucleotide deletion, which started just after the seventh transmembrane domain.  
So mGluR4b had a completely different predicted C-terminal tail compared to mGluR4a. The 
corresponding DNA and amino acid sequences are shown in Figure 19.  We hence examined the 
rat genome database for mGluR4 gene. The last several axons and introns are shown in Figure 
20; the 620 nucleotide deletion extends over the last two exons of the mGluR4 gene, but neither 
of the termini of the deletion fragment contains a typical exon/intron boundary signal (GT---
AG);  hence  mGluR4b  cannot  be  an  alternative splice  variant  of  mGluR4a.  Also,  a  stringent 
BLAST search of EST sequences did not reveal any other homologues, except for mGluR4a and 
the published mGluR4b variant. We therefore have to conclude that the mGluR4b variant does 
not exist, but represents a cloning artifact. Hence, only one form of mGluR4 exists, mGluR4a.                                
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Figure 19. The C-terminal tail sequences of mGluR4a and mGluR4b. The upper brace shows the position 
of  the  predicted  seventh  transmembrane  domain.  The  overline  shows  the  620  nucleotide  deletion 
described to yield mGluR4b-C. The bottom bracket shows the poly(A) signal. The predicted C-terminal 
domain sequences of mGluR4a and b  are indicated. Modified from Thomsen et al. (1997). 
7th transmembrane domain 
Poly(A) signal 
mGluR4a-C 
mGluR4b-C 
Figure 20. Structures of the last seven exons of the mGluR4 gene and the corresponding cDNA. The 
deletion  thought  to  create  mGluR4b  lies  inside  the  last  2  exons  and  does  not  contain  typical  intron 
boundary signals (5’ GT---AG 3’). 
TCCA-----------------TCCA 
deletion 
Gene 
cDNA 
 
Exon No. 2       3                                            4  5           6          7        8    
cds  mGluR4b-C                                
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4  DISCUSSION AND PROSPECTS 
To identify proteins that may interact with mGluR8, yeast two-hybrid screens were performed 
with  the  C-terminal  tails  of  both  mGluR8a  and  mGluR8b  as  baits.  About  thirty  candidate 
interacting proteins were found, five of them related to sumoylation: Pias1, Piasxβ, Piasγ, ube2a 
and sumo-1. Yeast mating verified that all these proteins interact with the C-termini of both 
mGluR8a and mGluR8b. GST pulldown and binary yeast two-hybrid assays revealed that Pias1 
was the most prominent interaction partner not only for mGluR8, but all group III mGluRs. 
Binary yeast two-hybrid assays argue agaist the possibility of group II mGluRs also serving as 
interacting  partners  for  Pias1.  In  vivo  sumoylation  assays,  combined  with  site-directed 
mutagenesis, confirmed that the C-terminal tail of mGluR8a could be sumoylated at K882. 
Of four components (one modifier + three enzymes) in the sumo-conjugation pathway, only E1 
was not found in the yeast two-hybrid screens. This is reasonable because E1 does not interact 
with substrates directly. E1 acts in the sumoylation pathway by activating sumo, then passing it 
to the conjugating enzyme E2 (See Appendix II, Figure 1). 
 
4.1  Prediction of Full-length mGluR8 Sumoylation 
In vivo  sumoylation  assays  revealed  that  GFP-mGluR8a-C  was  conjugated  to  sumo-1  upon 
overexpression of sumo-1 and the sumoylation machinery in mammalian cells. An intriguing 
question  would  be  whether  the  full-length  mGluR8  is  also  sumoylated  in  the  same  way.  A 
prediction of sumoylation sites of full-length rat mGluR8a (AAB09537) revealed eight possible 
sumoylation sites (http://www.abgent.com/doc/sumoplot, Table 8). Six of them are located in 
Table 8. Prediction of possible sumoylation sites of full-length mGluR8a 
 
No.  Position*  Group  Score 
1  K576        QLIPI IKLE WHSPW  0.94 
2  K882  RPNGE VKSE LCESL  0.93 
3  K68    VPCGE LKKE KGIHR  0.91 
4  K741  KARGV LKCD ISDLS  0.91 
5  K498       TNQLH LKVE DMQWA  0.91 
6  K57     LFPVH AKGE RGVPC  0.79 
7  K170    NILRL FKIP  QISYA  0.74 
8  K252   CIAQS QKIP REPRP  0.39 
 
*AA1-584 are predicted to be extracellular N-terminal region.                                
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the extracellular N-terminal region, and one in the second extracellular loop; thus all these sites 
are not available for conjugation by sumo-1 (Figure 21). K882 is the only predicted sumoylation 
site that lies intracellularly and has been identified as a sumoylation site in the current study. 
Therefore it is likely that K882 is the only sumoylation site of full-length mGluR8. 
 
4.2  Interacting Motifs of mGluRs and Pias1 
The  pull-down  assays  with  truncations  or  point  mutants  of  the  mGluR7a-  and  mGluR8a-C-
terminal tails showed that binding of Pias1 to the receptor C-termini can occur independently of 
the  presence  of  the  proposed  sumoylation  site  (mGluR7a-N38)  or  the  target  lysine  residue 
(mGluR8a-K882R, mGluR7a-K889R). Thus, it seems that a minimal binding sequence may exist 
outside  of  the  consensus  conjugation  site.  By  using  partial  constructs  of  mGluR8a-C  and 
mGluR7a-C,  this  minimal  binding  sequence  was  deduced  to  reside  within  six  amino  acids 
preceding  the  consensus  conjugation  site  (mGluR8a  875-880,  DRPNGE),  a  motif  that  is 
conserved among mGluR7 and mGluR8 isoforms and, to a lesser extent, in mGluR4. Notably, 
Figure 21. Prediction of transmembrane domain of rat mGluR8a (AAB09537). Protein sequence of full-
length mGluR8a was submitted to the following PredictProtein Sever: 
 
http://www.embl-heidelberg.de/predictprotein/predictprotein.html 
 
The prediction results are schematized in the figure. N- and C-terminal regions are indicated as NTD 
and CTD, respectively. Extracellular- (e1-3) and intracellular (i1-3) loops are indicated with brackets 
and numbers for AA sequence range. 
NTD 
(1-586) 
i1 
(605-623) 
i2 
(669-695) 
i3 
(768-785) 
e1 
(642-650) 
e3 
(804-819) 
e2 
(714-749) 
CTD 
(838-908)                                
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Pias1 binding was also found with mGluR6 in both yeast two-hybrid and pull-down assays. 
Among  group  III  mGluRs,  mGluR6  is  unusual  for  several  reasons:  it  is  localized 
postsynaptically,  is  exclusively  expressed  in  retina  and  lacks  the  ability  to  interact  with 
Ca
2+/calmodulin, which recognizes all other group III mGluRs (O'Connor et al., 1999; El Far et 
al., 2000; Airas et al., 2001). mGluR6 also lacks the consensus sumo-conjugation motif and 
harbours only two (PxxE) of the six amino acids within the DRPNGE motif common to all other 
group III mGluRs. If mGluR6 shares the motif for binding Pias1 with mGluR4, 7 and 8, these 
two  amino  acids  may  be  sufficient  to  mediate  Pias1-binding.  Alternatively,  other  more 
homologous motifs, including three-dimentional determinants, of the receptor C-terminal tails 
that are also present in mGluR6 may contribute to the binding of Pias1.  It is also possible that 
these receptors bind Pias1 at different regions. Group II mGluRs, which lack both the consensus 
sumoylation site and the proposed Pias1-interaction domain, did not show any interaction with 
Pias1 in the yeast two-hybrid system.  
The domains of Pias1 that mediate the interaction with group III mGluRs are not defined yet. 
The  fact  that  our  two-hybrid  screen  isolated  a Pias1  fragment  encoding  only  the  C-terminal 
amino acids 514-721 suggests that binding to the target sequence occurs downstream of the SP-
RING domain (residues 401-453) of Pias1 that is supposed to bind E2 (Kahyo et al., 2001).  
 
4.3  Possible Functions of mGluR Sumoylation 
An important question is what the physiological consequences of sumo-modification of mGluR8 
are. As no results from the current research can answer this question directly, some possibilities 
are raised here for consideration in the future.  
 
4.3.1  Alternative 1: Sumoylation Antagonizes other Modifications 
Lysine residues act as acceptors not only for sumo modification but also for ubiquitination and 
other  ubiquitin-like  modification  reactions;  moreover  they  are  also  sites  of  methylation  and 
acetylation  (Johnson,  2004;  Hay,  2005).  Unlike  sumoylation  that  happens  mostly  at  highly 
conserved motifs, ubiquitination, acetylation or methylation sites are not so restricted (DiAntonio 
and Hicke 2004; Roth et al. 2001; Cheng et al. 2005). Acetylation and methylation are common 
histone protein modifications (Cheng et al., 2005; Martin-Ruiz et al., 2001). They have not been 
reported to modify mGluR8. Sumoylation has been shown to antogonize ubiquitination of the                                
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same  Lys  residues  of  transcription  factor  NF-κB  (Desterro  et  al.,  1998),  NF-κB  essential 
modulator (NEMO) (Hay, 2004, 2005) and  proliferating cell nuclear antigen (PCNA) (Stelter 
and Ulrich, 2003). If antagonism between ubiquitination and sumoylation exists at mGluR8a, 
there should be ubiquitination at this receptor, or at least at some other mGluRs. An ubiquitin E3 
ligase, the mammalian homologue of Drosophila seven in absentia (Siah-1A), has been shown to 
interact with group I mGluRs within the region that also interacts with calmodulin (Hu et al., 
1999; Ishikawa et al., 1999). The binding of Siah-1A blocks calmodulin binding and mediates 
ubiquitination and subsequent degradation of group I mGluRs (Ishikawa et al., 1999; Moriyoshi 
et  al.,  2004).  Thus,  Siah1A  is  considered  to  be  a  selective  ubiquitin  ligase  that  mediates 
ubiquitination-dependent  degradation  of  group  I  mGluRs  and  thus  contributes  to  their 
posttranslational  down-regulation  (Moriyoshi  et al.,  2004).  As  binding  of  calmodulin  is  also 
common to Group III mGluRs and plays an important role in mGluR signalling (El Far and Betz, 
2002),  it  is  possible  that  the  ubiquitination  mediated  blockade  of  calmodulin  signalling  and 
degradation  of  the  receptors  also  happens  to  group  III  mGluRs.  As  the  interaction  between 
mGluR7a and Siah-1A was not proven by yeast two-hybrid (Ishikawa et al., 1999), it is possible 
that some other ubiquitin E3 ligase may bind and trigger ubiquitination of the receptor. In this 
case, the binding of Pias proteins and subsequent sumoylation may interfere with ubiquitination. 
Besides, it has been shown that PKA directly phosphorylates mGluR4a, mGluR7a and mGluR8a 
at single conserved serine residues within the N-terminal region of their tail domains (Cai et al., 
2001). It is not known, but possible, that the binding of Pias1 to the center of mGluR8a-C is 
related  to  binding  of  phosphorylation  and  dephosphorylation  enzymes  to  somewhere  of 
mGluR8a-C. 
 
4.3.2  Alternative 2: Sumoylation Interferes with Other Binding Proteins 
The C-termini of mGluRs are the binding sites for many proteins related to different functions of 
the  receptors:  targeting,  functional  recycling,  interaction  with  the  cytoskeleton,  membrane 
assembly, allosteric activation and signaling modulation of the receptors (Figure 22) (Fagni et al. 
2004). Not many binding partners of mGluR8a have been identified yet. It is known that N-
terminal  to  the  sumoylation  site  there  are  binding  sites  for  G-proteins  and  CaM,  which  are 
supposed  to  be  important  for  mGluR  signalling  (El  Far  et  al.,  2001),  as  discussed  above. 
Interestingly,  the  binding  site  of  Pias1  is  near  to  that  of  filamin  A,  a  protein  related  to  the                                
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cytoskeleton (Enz, R. 2002. Figure 22). Thus it appears possible that sumo conjugation may 
cause  detachment  of  mGluRs  from  the  cytoskeleton,  thereby  allowing  for  internalization  or 
redistribution of the receptors. 
 
4.4  Pias 1 may function as an Adaptor in the Sumoylation of mGluR8 
Sumo-1, ube2a and Pias proteins were all found in the yeast two-hybrid screens, but only Pias 
proteins were confirmed by GST pulldown to interact with C-termini of mGluR8a mGluR8b, 
whereas  recombinant  ube2a  and  sumo-1  failed  to  bind  mGluR8a-C  in  these  assays.  This  is 
Figure 22. Binding domains of mGluRs. Modified from Fagni et al. (2004). The figure represents the C-
terminus of the three groups of mGluRs. The dark and light blue bands indicate the homologous and 
divergent  amino  acid  sequences  within  a  given  mGlu gene.  Colored  boxes  represent  the  interaction 
domains of the indicated proteins. Calmodulin competes with Siah-1A on mGlu1a, mGlu5a and mGlu5b 
receptors, and with Gβγ subunits on mGlu4, mGlu7a, mGlu7b, mGlu8a and mGlu8b receptors. Other 
overlapping protein binding domains exist on  mGluR1a (homer, tamalin and  tubulin),  mGluR5a and 
mGluR5b (calmodulin with filamin-A), mGluR2, mGluR3 and mGluR4 (syntenin, GRIP, PICK1 and 
tamalin), but whether or not these protein bindings are competitive has not been established. GST pull-
down  assays  showed  interaction  between  tamalin  and  group-II  mGluRs,  but  co-immunoprecipitation 
experiments obtained from rat brain extracts did not confirm these interactions. Surprisingly, interactions 
of syntenin and GRIP with mGluR4 and mGluR7b were found in GST pull-down, but not in yeast two-
hybrid screen experiments. Abbreviations: CaM, Calmodulin; Siah-1A, seven in absentia homolog-1A; 
GRIP,  glutamate  receptor  interacting  protein;  PICK1,  protein  interacting  with  C  kinase  1.  Tamalin, 
syntenin, GRIP and PICK1 are PDZ domain-containing proteins.                                 
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consistent with the role each protein plays in the sumoylation pathway. Sumo-1 is the modifier; 
three enzymes catalyze its conjugation to a substrate, so no direct interaction between sumo and 
the substrate is needed for sumoylation. Nevertheless, an interaction is required between the 
sumo  molecule  and  the  substrate  on  the  areas  around  the  isopeptide  bond,  which  is  at  least 
permissive for bond formation. This interaction can be detected by the highly sensitive NMR 
chemical shift perturbance assay (Song et al., 2004). However, such an interaction may be too 
weak to be detected in GST-pulldown, especially under the stringent washing conditions used in 
the current experiments. The identification of sumo-1 as an interacting protein of mGluR8b in 
the yeast two-hybrid screen and of both mGluR8a and mGluR8b in the yeast mating assays 
might have resulted from sumo conjugation of the baits in yeast. The mammalian sumo-1 protein 
has been shown to function in yeast cells because it can rescue the lethality of the smt3 deletion 
yeast mutant (Takahashi et al., 1999).  
The sumoylation conjugating E2 enzyme ube2a functions as an intermediate in the sumoylation 
pathway: it accepts sumo from E1 and transfers it to the substrate with the help of E3. Ube2a 
may be able to bind the substrates via their sumoylation consensus sequences ΦKXE/D, but the 
interaction is considered to be weak and insufficient for efficient modification (Pichler et al., 
2004). Most proteins are sumoylated efficiently only in the presence of E3 ligases (Pichler et al., 
2004). The interaction between ube2a and the mGluR8 C-terminal tails detected in the yeast two-
hybrid sreens could be mediated by some other proteins in yeast cells, e.g. siz1 and siz2 that are 
abundant and mediate nearly all SMT3
1 conjugation in yeast.  
Pias1 and Piasγ showed strong interaction with the C-terminal tails of mGluR8a/b in both the 
yeast  two-hybrid  screens  and  GST-pulldown  assays.  The  interacting  fragments  of  all  Pias 
proteins found here are their C-terminal regions. This is consistent with many other observations 
which established the C-terminal domains of Pias proteins as important interaction regions for 
sumoylation substrates (Johnson, 2004). Hence, Pias proteins are thought to act as adaptors in the 
sumoylation pathway. They recruit the substrates through their C-terminal, or in fewer cases, N-
terminal  domains,  and  take  them  to  the  conjugating  enzyme  E2  by  their  RING  domains 
interacting with E2. 
 
                                                 
1 SMT3: yeast homologue of sumo-1. For more information, see the appendix II review.                                
  55   
4.5  Other Candidates 
There are some other proteins that were found in the yeast two-hybrid screens, but here have not 
been studied further in this thesis.  
 
4.5.1  Faf1 and Hipk3 
Faf1 (Fas-associated factor 1) was found as a candidate interacting protein of mGluR8b-C, and 
Hipk3  (homeodomain-interacting  protein  kinase  3)  of  both  mGluR8a-C  and  mGluR8b-C,  in 
yeast two-hybrid screens. Both Hipk3 and Faf1 interact with the cell surface death receptor Fas 
that leads to apoptosis (Rochat-Steiner et al., 2000; Ryu et al., 2003). Thus, Faf1 and HIKP3 may 
link mGluR8 to a function in cell fate determination. This seems to be consistent with the report 
that mGluR8-deficient mice are about 8% heavier than their wild-type age-matched controls after 
reaching  4  weeks  of  age  (Duvoisin  et  al.,  2005).  Notably,  Pias1  KO  mice  also  show  a  size 
change: they are smaller than their wild type littermates (Liu et al., 2004). Although Pias1 is an 
E3  ligase  for  many  proteins,  it  will  be  interesting  to  see  whether  the  weight  changes  after 
knockout of these two genes might be related; and especially, whether Faf1 and HIKP3 trigger 
the molecular machinery which controls animal weight. 
 
4.5.2  PKAi 
It is known that cAMP-dependent protein kinase (PKA) signalling is important for mGluR8 
regulation. mGluR8 has been shown to be phosphorylated by PKA, and activation of PKA by 
forskolin  inhibits  group  III  mGluR-mediated  responses  at  glutamatergic  synapses  in  the 
hippocampus  (Cai  et  al.,  2001).  In vivo  microdialysis  showed  that  intra-periaqueductal  gray 
(PAG) perfusion of (S)-3,4-DCPG, a selective agonist of mGlu8 receptor, increased glutamate 
and  decreased  GABA  extracellular  concentrations  (Marabese  et  al.,  2005).  The  effect  was 
abolished by intra-PAG perfusion with N-[2-( p-bromocinnamyl-amino) ethyl]-5-isoquinoline-
sulfonamide dihydrochloride (H-89), a PKA inhibitor (Marabese et al., 2005). The finding of 
PKAi (cAMP-dependent protein kinase inhibitor) as an interaction partner of mGluR8a in the 
yeast two-hybrid screen performed here suggests that there are endogenous proteins that may 
antagonize the effect of PKA by directly interacting with the receptor. Further investigations 
unravel how mGluR is coupled to the dual but diverging pathways of PKA signalling. 
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Figure 27. Schematic of generating fluorescence tagged sumo-1, ube2a an Pias1 constructs 
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Figure 28. Generation and conformation of GFP-mGluR8a-C-N24/-C44 constructs 
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K872R 
Figure 23. Generation and 
verification of KR 
mutants of GFP-
mGluR8a-C. 
A. KR mutants were 
generated by site-directed 
mutagenesis. Note that a 
Bgl II site is   induced 
around R882 (yellow 
dashed  underline in B). 
B. All single mutant sites 
were proven to be correct 
by DNA sequencing. 
C. K868/872R double 
mutant sites were verified 
to be correct by DNA 
sequencing. 
D. K868/872/882R triple 
mutant sites were 
controlled to be correct 
by DNA sequencing. 
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Figure 24. Generation and verification of full-length mGluR8a constructs.  
A.  pBK-CMVΔLac-mGluR8a  was  generated  by  shifting  a  full-length  rat  mGluR8a  cDNA  from  a 
pcDNA3 construct to pBK-CMV between NheI and XhoI sites, thus resulted deletion of the Lac-
promotor  in  the  vector;  and  was  further  mutated  with  primers  encoding  a  Myc  tag.  A  K882R 
substitution  was  introduced  by  shuffling  the  corresponding  fragment  from  a  GFP-mGluR8a-C-
K882R (mouse) plasmid. Note that new XhoI and BglII sites were introduced into the Myc tag and 
R882 sequences, respectively. 
B.  Myc tag was checked by DNA sequencing  to have been inserted at the correct position. 
C.  K882R substitution was also approved by DNA sequencing to be correct. 
D.  Asp905 (black box) was induced spontaneously from the mouse mGluR8a-C cDNA construct to 
substitute the Asn905 in the rat full-length mGluR8a construct.  
E.  The full-length Myc-mGluR8a-K882R was sequenced to be same as cDNA No. AAB09537 except 
for AA423 (black box), which is an  Arg in AAB09537,  but is a Lys  in  two DNA sequencing 
samples.  
F.  L423 (indicated by a red arrow) is common between mouse and human mGluR8, consistent with 
DNA sequencing results. Thus it is likely that AA423 in rat mGluR8 is also a Lys.  
G.  Expression of the full-length MycGluR8a was demonstrated by Western blotting using anti-Myc 
antibody, as a dimer about  200 kD. 
H.  The full-length MycGluR8a is incorporated into membrane after being transfected into HEK 293 
cells, demonstrated by anti-Myc staining. 
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Figure 25. Generation and verification of constructs with His-tagged proteins. 
A.  pQE30-6xHis-ube2a  was  generated  by  inserting  the  full-length  ube2a  cDNA  amplified  by 
PCR into pEQ30. 
B.   pQE30-6xHis-Pias1 was made by inserting the Pias1 from pCMV5 construct into pQE30. 
C.  pET28a-6xHis-sumo-1ΔC4  was  created  by  inserting  the  sumo-1ΔC4  fragment  from  the 
pET11a vectort into pET28a. 
D.  pcDNA3-6xHis-aos1 was constructed by inserting the 6xHis-aosl fragment from pET28a-aos1 
amplified by PCR into pcDNA3. 
E.  Verification of constructs A-D by DNA sequencing. 6xHis tags are indicated in red box. 
D 
pQE30-6xHis-Pias1: 
pQE30-6xHis-ube2a: 
pET28a-6xHis-sumo-1ΔC4: 
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Figure 26. Generation and verification of pBK-CMV- ΔLac-m8a-GFP construct. 
A.  A NheI site was introduced before the stop codon of full-length mGluR8a. GFP sequence was 
inserted at the end of mGluR8a cDNA sequence. 
B.  Verification of the sequence. GFP (green underline) follows the enc of mGluR8a (black underline) 
without stop codon. A stop coden follows the end of GFP. 
C.  mGluR8a-GFP incorporated into membrane after transfection into HEK293 cells. 
D.  Western blot of mGluR8a-GFP expressed in HEK293 cells, using anti-mGluR8a-C antibody. 
           *, monomer (135 kDa); **, dimer (270 kDa) of mGluR8a-GFP . 
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pJG4-5-sumo-1 
PCR 
SUMO-BamHI,s 
SUMO-HindIII,as 
pEC(/Y)FP-C1, 
pdsRed2-C1 
Bgl II/HindIII 
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Figure  27.  Schematic  of 
generating  fluorescence 
tagged  sumo-1,  ube2a  an 
Pias1 constructs. 
A.  Sumo-1  constructs  were 
generated by inserting the 
sumo-1  amplified  by  PCR 
into corresponding vectors. 
B.  Ube2a  constructs  were 
created  by  inserting  the 
ube2a  amplified  by  PCR 
into corresponding vectors. 
C.  GFP-Pias1  construct  was 
assembled by inserting the 
Pias1  from  pCMV5 
cnstruct into pEGFP-C2. 
D.  CFP-  and  ds-Red-Pias1 
constructs  were  made  by 
inserting  the  Pias1  from 
pCMV5  cnstruct  into 
corresponding vectors. 
pEC(/Y)FP-C1-Pias1  SalI 
pEC(/Y)FP-C1 
pCMV5-Pias1 
ClaI 
EcoRI 
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pEGFP-8a-tail 
EcoRIm8tC44,s 
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pEGFP-m8a-tail-C44 
Figure 28. Generation and conformation of GFP-mGluR8a-C-N24/-C44 constructs. 
A.  pEGFP-mGluR8a-C-N24 was constructed by inserting N24 fragment amplified by PCR 
into pEGFP-C2. 
B.  pEGFP-mGluR8a-C-C44 was created by inserting C44 fragment amplified by PCR into 
pEGFP-C2. 
C.  Proteins expressions were checked by transfection into HEK cells, followed by Western 
blotting using anti-GFP antibody. All protein bands were in the appropriate molecular 
weight range.  
  74 
APPENDIX II: REVIEW 
 
SUMOYLATION: STRUCTURES AND MECHANISMS 
 
 
SUMOYLATION PATHWAY ....................................................................................................................75 
SUMOYLATION MACHINERY: SUMO AND ENZYMES.....................................................................75 
Sumo..............................................................................................................................77 
E1...................................................................................................................................79 
E2...................................................................................................................................84 
E3...................................................................................................................................87 
Pias proteins..............................................................................................................87 
RanBP2.....................................................................................................................90 
Pc2............................................................................................................................91 
SUMOYLATION COMPLEX .....................................................................................................................92 
Sumoylation model.........................................................................................................92 
Prospective of the Model................................................................................................95 
REFERENCES: ............................................................................................................................................96 
  
  75 
Sumoylation  is  a  posttranslational  modification  in  which  sumo
1  (small  ubiquitin-like 
modifier) proteins are covalently bound to the ε-NH2 group of Lys residues of substrates 
(Melchior, 2000; Johnson, 2004). Sumoylation has been shown to modify a large number of 
proteins  with  important  roles  in  many  cellular  processes,  including  gene  expression, 
chromatin  structure,  signal  transduction  and  maintenance  of  the  genome  (Gill,  2004). 
Sumoylation is mechanistically related to ubiquitination, so many studies were performed 
using  ubiquitination  as  a  model  system.  The  structures  of  most  proteins  and  protein 
complexes involved in sumoylation and other related modifications have been analysed by X-
ray  crystallography  or  NMR  chemical  shift  perturbation,  thus  provide  insight  into  the 
mechanism of sumoylation. This review describes the structures and functions of modifiers 
and enzymes involved in the ubiquitin, sumo and Nedd8 modification pathways. Some of the 
descriptions of structures are cited from the corresponding original research papers. 
 
SUMOYLATION PATHWAY 
The  enzymatic  machinery  that  adds  and  removes  sumo  is  related  to  the  ubiquitination 
machinery (Gill, 2004). Like ubiquitin, sumo proteins are also expressed as precursors that 
need to be proteolytically processed by C-terminal hydrolases to make the C-terminal Gly-
Gly motif available for conjugation. This step is called maturation (Figure 1A). 
The sumoylation procedure requires sumo and three enzymes: sumo-activating enzyme (E1), 
sumo-conjugating  enzyme  (E2)  and  sumo  ligase  (E3)  (Gill,  2004;  Johnson,  2004),  which 
catalyze three different steps (Figure 1A). The first one is called activation, which actually 
includes  two  sub-steps:  adenylation  and  thioester  transferrence  within  E1.  As  a  result,  a 
thioester bond is formed between the COOH group of the sumo C-terminal Gly residue and 
the activating residue Cys of E1. ATP and Mg
2+ are required for sumo activation. In the 
second conjugation step, the sumo is transferred from E1 to the active Cys site of E2, forming 
an E2-sumo thiolester intermediate. Finally, sumo is transferred in a ligation reaction to the 
amino group of a substrate lysine with the assistance of a sumo-ligating enzyme (E3). 
The isopeptide bond between sumo and the substrate can be cleaved by isopeptidases. This 
step is called de-sumoylation (Figure 1A). The isopeptidases are also C-terminal hydrolases 
that catalyze sumo maturation (Johnson, 2004).   
SUMOYLATION MACHINERY: SUMO AND ENZYMES 
                                                 
1  Abbreviations: sumo, small ubiquitin-like modifier; Ubl, ubiquitin-like modifier; UbL, ubiquitin-like domain; E1, 
activating enzyme; E2, conjugating enzyme; E3, ligase; uba, ubiquitin activating enzyme; ubc, ubiquitin conjugating enzyme.    
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Fewer components or isoforms are known for the early enzymatic steps in the sumoylation 
system  than  in  the  ubiquitination  system.  For  ubiquitination,  there  is  only  one  form  of 
ubiquitin, one E1, a significant but limited number of E2 enzymes, and a large number of E3 
enzymes. Several E3 proteins interact with the same E2, and several E2 enzymes may also 
interact with the same E3. Each E3 recognizes a set of substrates that shares one or more 
ubiquitination  signals,  and  cooperates  with  one  or  a  few  E2  (Pickart,  2001).  In  the 
sumoylation system, four sumo proteins have been identified; substrates are coupled by one 
E1, one E2 and several E3 enzymes. A similar conjugation mode is found for Nedd8, another 
Figure 1. Sumoylation machinery. A. The sumo conjugation pathway. Free sumo is generated from either 
maturation of the sumo precursor or dissociation from a sumoylated substrate. For sumo conjugation, sumo 
is firstly activated by and forms a thioester bond with the activating enzyme E1, then transferred to the 
conjugating  enzyme  E2  and  at  last  to  the  substrate,  B.  Schematic  diagram  of  individual  steps  in  the 
sumoylation cascade. C. Schematic of individual steps in the neddylation cascade. A and B are modified 
from Johnson (2004). C is modified from Huang et al. (2004a). 
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ubiquitin-like modifier. The enzymes involved in sumoylation and neddylation
2  are shown in 
Figure 1B and 1C, respectively. 
Sumo 
It is interesting that sumo, E1 and E2 of sumoylation pathway were all cloned in 1995, but 
their  function  in  sumoylation  were  all  identified  two  years  later  (Melchior,  2000).  Four 
mammalian sumo proteins have been identified so far. The alignment of sumo proteins with 
ubiquitin and Nedd8 is shown in Figure 2. Sumo-1 has only18% amino acid sequence identity 
with ubiquitin, but their structures are quite identical. Sumo-1 shares about 43% sequence 
identity with sumo-2 and sumo-3, which have 96% sequence identity. Phylogenetic analyses 
indicate that the sumo-3 gene derives from the sumo-2 gene (Su and Li, 2002). Sumo-4 shares 
87% sequence homology with sumo-2. Sumo-1 does not contain a consensus sumoylation 
motif ΦKXE
3, whereas the other three do. Thus, sumo-2 and, to a less extent, sumo-3, have 
been shown to form polymer chains, while sumo-1 has not (Tatham et al., 2001; Johnson, 
2004). 
                                                 
2  Neddylation, the conjugation of Nedd8 (Neural cell expressed developmentally down-regulated protein 8) to the substrate. 
3  ΦKXE , a consensus motif among many sumoylation sites, where Φ is a large hydrophobic amino acid; K, the Lys residue; 
X, any amino acid; E/D, glutamate or aspartate. 
Figure 2. Alignment of ubiquitin, sumo-1 to 4, SMT3 and Nedd8. All sequences are of Homo sapiens, 
except  for  SMT3  form  Saccharomyces  cerevisiae.  The  red  box  indicates  consensus  sumoylation 
motifs. The blue box indicates residues compatible for binding of corresponding E1.  
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Sumo-1/-2/-3 are found in all eukaryotes and are required for viability of most eukaryotic 
cells,  including  budding  yeast,  nematodes,  fruit  flies,  and  vertebrate  cells  in  culture.  In 
multicellular  organisms,  sumo  conjugation  takes  place  in  all  tissues  at  all  developmental 
stages (Johnson, 2004). Sumo-1 to 3 were shown to be localized at the nuclear membrane, 
nuclear bodies and cytoplasm, respectively (Su and Li, 2002). The distribution of sumo-4 has 
not yet been reported. Sumo-4 mRNA was detected mainly in the kidney (Bohren et al., 2004).   
E1 and E2 do not appear to have any substantial preference for either sumo-1 or sumo-2/3 
(Tatham et al., 2005). Sumo-1 is the modifier of most substrates identified. Sumo-2 and -3 are 
assumed to be functionally identical, and only a few sumo-2/-3 modified substrates have been 
found so far (Johnson, 2004). It was shown that PML
4  is covalently modified by all three 
sumo proteins (Kamitani et al., 1998). The sumo-2 chain has been observed on the histone 
deacetylase HDAC4 in cells; it forms a di-sumoylated conjugate that disappears when the 
sumo attachment site in sumo-2 is mutated (Tatham et al., 2001). Aβ production has been 
found to decrease with overexpression of sumo-3, and increase with dominant-negative sumo-
3. It is interesting that K11R mutant of sumo-3, a mutant of the consensus sumoylation motif 
that  abolishes  poly(sumo-3)  chain  formation  and  hence  can  only  be  monomerically 
conjugated to target proteins, has an opposite effect on Aβ generation (Li et al., 2003). 
The crystal structures of ubiquitin, SMT3, sumo-1-3 and Nedd8 all resemble the ββαββαβ 
fold (Figure 3A-B) (Bayer et al., 1998; Whitby et al., 1998; Huang et al., 2004; Ding et al., 
2005), and the polypeptide back bones match well when they are overlayed (Figure 3C). 
Hydrophobic  residues  are  located  at  the  helix-sheet  interface,  are  highly  conserved,  and 
contribute to the maintenance of the globular and compact fold (Ding et al., 2005). Similarly, 
the consensus Lys sites of SMT3 and sumo-2/3 and the two glycine residues at the C-terminus 
of ubiquitin, SMT3 and all sumo proteins are highly conserved (Ding et al., 2005). 
A  comparison  of  sumo-2  and  sumo-1  surfaces  shows  a  region  near  the  C-terminus  with 
significantly  different  charge  distributions.  This  may  explain  the  distinct  intracellular 
locations of these sumo isoforms (Huang et al., 2004). Both ubiquitin and sumo-2/3 can form 
poly-chains. The Lys sites for poly-ubiquitin formation are located in the compact core of the 
ubiquitin molecule. Conversely, the consensus Lys sites of sumo-2, -3 and -4 for poly-sumo 
chain formation lie in the N-terminal free strand. So it can be imagined that there are much 
larger contact areas between ubiquitin molecules than between sumo molecules. The function 
of this difference remains to be understood. 
                                                 
4 PML, a RING finger protein with tumor suppressor activity, has been implicated in the pathogenesis 
of acute promyelocytic leukemia (PML) that arises following a reciprocal chromosomal translocation 
that fuses the PML gene with the retinoic acid receptor a (RARa) gene.  
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Sumo-1 conjugation onto substrates or catalytic enzymes always occurs with its C-terminus. 
Eleven residues of sumo-1 have been shown to aid in direct contacting with uba2, a subunit of 
sumoylation E1 ligase; seven of those residues lie in the very C-terminal tail (Lois and Lima, 
2005).  The  first  two  β-sheets  and  the  first  helix  are  also  important  for  the  contact  with 
substrates such as DNA glycosylase, ube2-25k, and isopeptidase SENP2 (Reverter and Lima, 
2004; Baba et al., 2005; Pichler et al., 2005). The functions of other regions of sumo proteins, 
especially the N-terminal free loops that make sumo proteins distinct from ubiquitin, are still 
unknown.   
E1 
The activating enzyme E1 facilitates the conjugation of ubiquitin and ubiquitin-like proteins 
through  adenylation,  thioester  transfer  within  E1,  and  thioester  transfer  from  E1  to  the 
conjugating enzyme E2 (Lois and Lima, 2005). Ubiquitin, sumo and Nedd8 all are activated 
by one isoform of E1. But unlike the ubiquitin specific E1 enzyme that is a monomer uba1, 
the E1s involved in the sumo and Nedd8 modification pathways are all heterodimers of two 
subunits. Sumo specific E1 enzyme is a complex with two subunits: aos1 and uba2. Nedd8 
specific  E1  enzyme  is  also  a  complex  with  two  subunits:  APPBP1  and  uba3.  Aos1  and 
APPBP1 resemble the N-, uba2 and uba3 the C-termini of ubiquitin E1. The alignment of 
uba1, aos1/uba2 and APPBP1/uba3 is shown in Figure 4, 5A.    Aos1 is composed of only one   
A  B  C 
Figure 3. Structures of ubiquitin (A) and sumo-1 (B). C. Backbone superposition of the 
core structures of sumo-3 C47S (red), sumo-1 (green), and ubiquitin (blue). A and B are 
taken from Gill, (2004), C from Ding et al., (2005). 
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Figure 4. The alignment of aos1-uba2, APPBP1-uba3 complexes and uba1, the activating enzymes of sumo, 
Nedd8 and ubiquitin, respectively. The pink box (AA370-375 for aos1-uba2 complex) indicates locations of 
nucleotide binding center. The blue box (AA495 for aos1-uba2 complex) indicates residues permissive for 
corresponding modifiers. The red box (AA519 for aos1-uba2 complex) indicates  catalytic residues. All 
protein sequences are of Homo sapiens.    
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domain that participates in adenylation of sumo. Uba2 includes three domains: the catalytic 
Cys  domain,  the  adenylation  domain  and  the  ubiquitin-like  (UbL)  domain  which  is 
structurally similar to ubiquitin and other ubiquitin-like modifiers (Lois and Lima, 2005). The 
uba2 adenylation domain, which is separated by the catalytic Cys domain into two parts, 
forms  a  pseudosymmetric  heterodimer  with  the  aos1  subunit.  Sumo-1  is  recognized 
exclusively by residues emanating from uba2, as no direct interactions are observed between 
sumo-1 and the aos1 subunit (Lois and Lima, 2005). The UbL domain of E1 shows strong 
interaction with E2, which is considered to be essential for recruiting E2 to E1 (Lois and 
Lima, 2005). The C-terminal extension of uba2 is not conserved in all E1 enzymes. The yeast 
uba2 C-terminal extension contains a nuclear localization signal (NLS) (Dohmen et al., 1995). 
APPBP1  has  two  domains:  the  adenylation  domain  resembles  aos1,  and  the  Cys  domain 
resembles part of uba2. Ubiquitin E1 protein uba1 contains all domains that sumo or Nedd8 
E1  enzyme  complexes  share.  The  alignment  of  aos1/uba2  and  APPBP1/uba3  with  uba1 
reveals that they may be derived from a common ancestor with different allocations of the 
functional domains to the subunits (Figure 4, 5A).   
The structure of the mammalian Ubl activating enzyme Nedd8 E1 complex APPBP1/Uba3 
was  published  in  2003  (Walden  et  al.,  2003a).  Expectedly,  the  sumo  activating  enzyme 
complex aos1/uba2 was found to resemble that of APPBP1/Uba3 (Lois and Lima, 2005). Part 
of the ubiquitin E1 protein was also successfully crystallized recently, including the ubiquitin-
binding domain and parts of the cysteine and the adenylation domains (Szczepanowski et al., 
2005).  Its  corresponding  regions  resemble  those  of  the  former  two  complexes.  The  E1 
structure  contains  a  big  groove  with  the  adenylation  domain  at  the  base,  UbL  and  Cys 
domains on both sides (Figure 5B). The adenylation domain has a typical Gly-x-Gly-x-x-Gly 
nucleotide binding motif (Walden et al., 2003b), which is conserved among ubiquitin, sumo 
and Nedd8 activating enzymes (Figure 4). One molecule of ATP is located in a pocket close 
to this motif. The upper part of the groove is further divided into two clefts by a loop (LCA) 
between the Cys domain and the adenylation domain. The catalytic site Cys173 lies in the 
Cys domain side of LCA. Cleft 1 is the space between the ubiquitin-like domain and part of the 
catalytic cysteine domain. Cleft 2 has the left portion of the catalytic cysteine domain as its 
only wall and is open to one side of the complex (Lois and Lima, 2005).   
Despite of the high similarities among the structures of all known Ubls and corresponding 
E1s, the modifiers bind to their enzymes very specifically. Prerequisite for this specificity are 
pairs of residues between the modifiers and the corresponding E1s (Walden et al., 2003b). 
The corresponding residues of all Ubls are at position –5, that is, a Glu in sumo-1, a Gln in  
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sumo-2/3/4,  an  Ala  for  Nedd8  and  an  Arg  for  ubiquitin  (Figure  2).  The  corresponding 
residues are Thr495 in uba2, Arg190 of uba3, and Gln608 of ubiquitin E1 (Figure 4).   
 
Actually  these  pairs  of  residues  do  not  show  strong  interactions,  they  just  function  as 
permissive factors. Ubiquitin cannot bind to the APPBP1-Uba3 complex because its Arg72 is 
repelled by Arg190 of uba3. An ubiquitin carrying an R72A mutation can bind APPBP1-
Uba3, whereas an A72R mutation of Nedd8 can not bind uba3 any more (Walden et al., 
2003b). More interestingly, the -5 residue of Nedd8 is also specific for recognition by Nedd8 
Figure 5, Structure of  the sumo  activating enzyme E1. A. Schematic representations of sumo  E1 
complex aos1/uba2, Nedd8 E1 complex APPBP1/uba3 and ubiquitin E1 uba1. Pink, light red and deep 
red  columns  repressent  adenylation,  Cys  and  ubiquitin-like  domains,  respectively.  Catalytic  Cys   
sites are colored in yellow. B. Structure of human aos1/uba2 complex. The complex contains a big 
groove that is divided into 2 clefts by the free loop L10. Adenylation, ubiquitin-like (UbL) and Cys 
domains are marked by brackets. The catalytic residue Cys173 (red) lies at the Cys domain end of 
L10. An ATP molecule is bound to the nucleotide binding motif. C. Side view of B. One sumo-1 
molecule bound at the nucleotide binding center. B-D are modified from the NCBI structure 1Y8R 
depicted by Lois and Lima ( 2005). 
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specific protease NEDP1 (Shen et al., 2005). Note that the sumo E1 enzyme catalyse all four 
sumo isoforms, but the corresponding –5 residues are different between sumo-1 and somo-
2/3/4. It is unclear whether Glu in sumo-1 and Gln in sumo-2/3/4 at the aligned position make 
any difference in these sumo isoforms interacting with E1.   
E2 
All sumo proteins share a conjugating enzyme E2, which is called ubc9 for yeast and human, 
and also called ube2i or ube2a in other species. While mouse and human ubc9 proteins are 
identical, there is a ~56% identity between the mammalian and S. cerevisiae orthologues 
(Dohmen,  2004).  Sumo  E2  is  also  of  high  homology  to  the  E2  enzymes  of  Nedd8  and 
ubiquitin. The alignment of sumo E2 ubc9, Nedd8 E2 ubc12 and a ubiquitin E2 ubcH7 is 
shown in Figure 6.   
 
Most E2 enzymes, including ubc9, ubc12, ubcH7 and some other ubiquitin E2s, contain a 
conserved  150-residue  αβββββ(ββ)ααα  motif  named  ubc  superfold,  and  differ from  one 
another only by N- and/or C-terminal extensions and/or small insertions within the ubc core 
(Jentsch, 1992; Tong et al., 1997; Bernier-Villamor et al., 2002). The superfold of ubc9 is 
shown in Figure 7A. It contains four α-helices and six β-strands. α1, α2 and α3/4 cover three 
sides of the molecule, and the antiparallel β-sheet formed by β1-4 strands cover another side. 
Still two sides are covered by loose strands, one surrounding the active residue Cys93 that is 
Figure 6. The alignment of conjugating E2 enzymes.    All protein sequences are of Homo sapiens. 
Red  box  (AA93  for  ubc9)  indicates  catalytic  residues.  Ubc9,  ubc12  and  ubcH7  are  conjugating 
enzymes for sumo, Nedd8 and ubiquitin, respectively.  
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situated close to the middle of a long extended stretch between the fourth β-strand and the 
second α-helix (Tong et al., 1997).   
Figure 7. Structures of E2 conjugating enzymes with their binding partners. A. Ubc9, modified from 1U9A 
by Tong et al., (1997). It consists of a1b1-6a2-4 , the b1-4 stretsches form an antiparallel sheet, a1-3 are 
located on different sides. The catalytic Cys93 lies on a free loop in a crevice formed by L6 (the longest 
loop between b6 and a2) and L7 (a long loop between a2 and a3). B. UbcH7 (yellow) bound with RING 
domain (blue) of Cbl, modified from 1FBV by Zheng et al. (2000). An interface is formed between ubcH7 
a1+L3+L6  and  cbl  RING  L1+L2+a.  C.  Ubc9  (yellow)  and  sumo-1  (blue)  in  the  sumo-ubc9-RanBP2-
RanGAP1  complex,  with  the  sumo-1  b-sheet  located  near  ubc9  a2.  Modified  from  Reverter  and  Lima 
(2005). Note that sumo-1 is not conjugated with ubc9 in this complex, but with RanGAP1 as shown in 
figure 8. D. Ubc9 (blue) and RanBP2 (IR1 domain, yellow) in the sumo-ubc9-RanBP2-RanGAP1 complex. 
N-terninal IR1 contacts with L1 and b-sheet of ubc9. E.Ubc12 (blue) bound with the ubiquitin-like (UbL) 
domain (yellow) of uba3. Ubc12 a1 resides in a groove formed by a13 and the b-sheet of the uba3 ubiquitin-
like  domain.  Modified  from  Huang  et  al.  (2004a).  F.  Ubc9  and  RanGAP1  in  the  sumo-ubc9-RanBP2-
RanGAP1 complex, the contact regions are around a4. 
C93
3  
  86 
 
In the sumoylation pathway (Figure 1), E2 functions as an intermediate, thus it interacts with 
nearly all other proteins. It has at least 5 binding sites related to sumoylation:   
1. The catalytic region that contains the catalytic site Cys93 and has a groove to hold the 
sumo-1 C-terminus (Figure 7C) (Liu et al., 1999). The binding of sumo at this site is the result 
of E2 interacting with E1. As modifiers and E1 interact specifically, ubiquitin or other Ubls 
cannot bind ubc9 at this site, and vice versa.   
2. The α1  regions  that  contain  the α1-helix  and  the  surrounding  residues  of  the  β-sheet. 
Similar regions in Nedd8's E2 (ubc12) are found bind the C-terminal ubiquitin-like domain of 
Nedd8's uba3 subunit in a firm and special way (Huang et al., 2005). Four of the five β-
strands and the kinked α-13 helix of the uba3 ubiquitin-like domain form a W-shaped surface 
of two grooves, which cradles ubc12's long α-helix along its entire length and part of the 
ubc12  α1β1  loop,  respectively  (Figure  7E) (Huang  et  al.,  2005). The  uba2  ubiquitin-like 
domain has also been shown to strongly interact with ubc9 (Lois and Lima, 2005). Although 
not proven, it is likely that ubc9 binds to the ubiquitin-like domain of uba2 in a similar way as 
ubc12 bind to uba3. Thus E1 and E2 may form a complex which acts as the core of the 
sumoylation machinery (See “SUMO COMPLEX”).   
3. The region below α1 that consists mainly of the N-terminal extension of α1 and the loop 
between  β2  and  β3,  and  between  β6  and  α2  (Figure  7B).  In  the  structures  of  ubiquitin 
conjugating enzymes, this is the region that interacts with both HECT- and RING-domains of 
ubiquitin  E3 ligases  (Huang  et  al.,  1999;  Zheng  et  al.,  2000),  and  thus  it  seems  to  be  a 
common site for E2-E3 binding. As no structure of the Pias RING domain is available, we 
take  the  structure  of  ubcH7-Cbl
5  as  the  model  of  E2-E3  binding,  and  suppose  that  ubc9 
interacts with the RING domain of Pias proteins in a similar way. In the ubcH7-Cbl structure, 
the apexes of the ubcH7 L3 and L6 loops reside contain a shallow groove formed by the α-
helix and the two zinc-chelating loops (L1 and L2) of the Ubl-RING domain (Figure 7B) 
(Zheng et al., 2000).   
4. The four-stranded β–sheet. In the sumo-1-ubc9-RanBP2-RanGAP1 complex, the ubc9 β–
sheet is the binding area for RanBP2 IR1 domain (Figure 7D) (Tatham et al., 2005).   
5.  The  C-terminal α3,4  region  that  binds  to  the  substrates.  RanGAP1  is  the  only  known 
substrate with a second binding site for ubc9 (Pichler et al., 2004), and binds ubc9 at the α3 
                                                 
5 Cbl, a ubiquitin E3 ligase containing a RING domain. It attenuates signaling by the activated PDGF, 
EGF, and CSF-1 receptor tyrosine kinases (RTKs) by inducing their ubiquitination and subsequent 
degradation by the proteasome.  
  87 
region (Figure 7F) (Bernier-Villamor et al., 2002; Tatham et al., 2003; Reverter and Lima, 
2005).   
 
E3 
After activation, sumo is transferred from E1 to E2, and is then ready to conjugate with the 
substrate. The last step is completed with the help of the E3 ligase. Initially there was some 
doubt about whether E3 is needed in the last step, because sumo conjugation can take place in 
vitro in the absence of the E3. However, the vast majority of sumoylation in yeast is E3-
dependent, and E3 enhances sumo attachment in vitro to all substrates that have been tested 
(Johnson, 2004). 
A  common  characteristic  of  E3  ligases  from  both  the  ubiquitin  and  sumo  systems  is  the 
existence of a nonproductive automodification reaction whereby sumo (or ubiquitin) is ligated 
from the E2 onto a lysine within the E3 itself in preference to a substrate molecule (Tatham et 
al.,  2005).  The  function  of  E3  auto-modification  is  unknown.  It  is  possible  that  the 
autosumoylation of E3 is the prerequisite for E3 recruitment of the substrate. 
E3 is the largest group of enzymes in the modification pathway. It is estimated that there are 
more  than  100  E3  ligases  in  the  human  genome,  but  only  a  few  E3  ligases  have  been 
characterized at the molecular level (Chin et al., 2002). About ten E3 ligases have been found 
to be involved in sumoylation, less is known for neddylation. Ubiquitin ligases can be broadly 
subdivided into two groups based on the presence of either a RING (really interesting new 
gene) or HECT (homologous to E6AP carboxyl terminus) structural motif. RING-containing 
E3 ligases bind both E2 and a particular target, whereas HECT-containing E3 form ubiquitin-
thioester  complexes  before  conjugation  of  ubiquitin  to  targets  (Pickart,  2001).  The 
sumoylation E3 ligases are devided into three groups. The biggest group, Pias proteins, also 
contain  RING  domains,  whereas  HECT  domain-containing  E3  ligases  have  not  been 
identified for sumoylation. Two additional groups of sumo ligases, the polycomb protein Pc2 
and the nucleoporin RanBP2, do not belong to either RING or HECT class ligases (Tatham et 
al., 2005). As discussed later, these three groups of ligase actually differently in sumoylation. 
Pias proteins 
Pias proteins are the largest group of sumo E3 ligases up to now. They were first identified as 
inhibitors of activated STAT (signal transducers and activators of transcription) (Chung et al., 
1997). Later on, they were shown to interact with and modulate several other proteins, and  
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more importantly, act as E3 ligases in sumoylation (Melchior et al., 2003). Pias proteins act 
not  only  as  sumoylation  E3  enzymes,  e.g.,  Piasx  can  coactivate  Elk-1  in  an E3  activity-
independent manner (Yang and Sharrocks, 2005). 
 
Four  mammalian  genes  encoding  Pias  proteins  have  been  described:  Pias1  (also  called 
GuBP), Pias3, Piasx, and Piasγ. Pias3 has a splice variant called KChaP, and Piasx also 
produces  two  isoforms  derived  from  alternative  splicing,  designated  Piasxα  (ARIP3)  and 
Piasxβ (Miz1). Pias1 and Pias3 are ubiquitously expressed, whereas Piasx and Piasy appear to 
be  found  primarily  in  testis.  All  of  the  Pias  proteins  localize  to  intranuclear  dots,  and 
colocalize, at least in part, with PML nuclear bodies (Johnson, 2004). Pias1 contains a N-
Figure 8. Schematic representation of    the domains of sumoylation E3 ligases. A. Pias. A typical Pias 
protein  contains  a  N-terminal  SAP  domain,  a  C-terminal  domain  (CTD),  a  sumo-interaction  motif 
(SIM)  and  a  SP-RING  domain.  B.  RanBP2,  modified  from  Matunis  and  Pichart,  (2005).  RanBP2 
contains a leucine-rich domain, four RanBP1 homologues (RBD), a region containing eight Zinc-finger 
motifs and the sumo E3 ligase domain BPΔFG, which consist of two internal repeats (IR) and a middle 
(M) domain. C. Pc2, drawn according to Kagey et al., (2005.) It contains three domains related to 
sumoylation of CtBP,  an uncharacterized  E3 domain, a PIDLR  motif for CtBP binding, and a ubc 
binding domain in between. 
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terminal SAP (SAR
6, Acinus, Pias) domain, SP-RING domain (Siz/Pias-RING), SIM (sumo 
interaction motif), and a highly divergent C-terminal domain (Figure 8A). The SAP domain is 
known to bind DNA and some proteins, such as the tumor suppressor p53 (Okubo et al., 
2004) and Lymphoid enhancer factor 1 (Sachdev et al., 2001). NMR spectroscopy showed 
that the NTD forms the four-helix SAP domain. One end of the four-helix bundle is the 
binding site for DNA and is thought to fit into the DNA minor groove (Okubo et al., 2004). 
The SIM domain has been implicated in directly binding sumo. It is an 11-amino acid motif 
that contains a central serine doublet separated by one amino acid, thus called SXS motif. On 
the N-terminal side, the SXS triplet is flanked by predominantly hydrophobic amino acids, 
and on the C-terminal side by acidic amino acids (D/E). Alanine replacement analysis shows 
that both the serines and the acidic C-terminal residues are crucial for interaction with sumo-1 
(Minty  et  al.,  2000).  Deletion  of  the  SIM  domain  has  little  effect  on  the  ability  of  Pias 
proteins  to  promote  sumo  conjugation,  but  it  can  affect  their  localization  and  activity  in 
transcriptions (Sachdev et al., 2001; Kotaja et al., 2002). The CTDs of Pias proteins are often 
found to interact with sumoylation substrates, e.g. the tumor suppressor homologue p73α and 
interferon regulatory factor-1 (IRF-1) (Minty et al., 2000; Nakagawa and Yokosawa, 2002); 
so,  it  is  generally  considered  to  be  a  substrate  specific  domain  (Johnson,  2004).  A 
conspicuous feature of Pias proteins is the SP-RING finger domain that is located in the 
middle of the protein. RING fingers have been defined by the consensus sequence Cx2Cx(9–
39)Cx(1–3)Hx(2–3)C/Hx2Cx(4–48)Cx2C, with the Cys and His side chains representing zinc 
binding sites (Figure 9A-B) (Pickart, 2001; Capili et al., 2004). It is known that SP-RING 
domains of Pias proteins interact with sumo conjugating enzyme E2 (Kahyo et al., 2001; 
Melchior et al., 2003; Johnson, 2004). But no structure of Pias protein RING domain has been 
identified. The ubiquitin E3 ligase Cbl RING domain structure consists of a three-stranded β-
sheet, an α-helix, and two large zinc-chelating loops. The helix and the two loops form a 
groove, into which the L1 and L2 loops of the E2 protein ubcH7 can bind (Figure 9C) (Zheng 
et al., 2000). 
Unlike Pias proteins that contain binding sites for both the substrates and E2, most ubiquitin 
E3  are  complexes  of  several  proteins,  and  the  binding  sites    for  E2s  and  substrates  are 
separated in different subunits. For example, in the Rbx1-Cul1-Skp1-Skp2 E3 complex, Rbx1 
                                                 
6  SAR, scaffold-associating regions. Interphase chromatin is arranged into topologically separated domains 
comprising gene expression and replication units through genomic sequence elements, so-called SAR regions. 
SAR regions are located near the boundaries of actively transcribed genes and were shown to influence their 
activity.  
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binds  E2,  and Skp2  binds  the  substrate  β-catenin  (Wu  et  al.,  2003).  Recently,  two  other 
proteins have been found to function as sumo ligases. They form a large complex with other 
proteins, and may thus, similar to ubiquitin E3s, be functional in large E3 complexes. One is 
the yeast protein Mms21 and its human homolog NSE2a (Potts and Yu, 2005; Zhao and 
Blobel, 2005). The other is topors, a protein originally identified as cellular binding partner of 
DNA topoisomerase I and of p53, recently found to function as an ubiquitin E3 ligase for the 
sumoylation of p53 and a variety of other unidentified cellular proteins (Weger et al., 2005). 
Those newly found E3 ligases also contain RING domains, but at different positions. Both 
Mms21 and NSE2 have RING domains at their C-termini, topors has a RING domain at its N-
terminus. As they do not show any homologue with any of the known Pias proteins, they 
might belong to new families of sumo E3 ligases.   
 
RanBP2 
The nuclear pore complex protein Ran binding protein 2 (RanBP2) is neither a HECT- nor 
RING-type E3 ligase. It was previously found to catalytically enhance sumoylation of the 
nuclear body component (Pichler et al., 2002). RanBP2 directly interacts with the E2 enzyme 
ubc9 and strongly enhances sumo-1-transfer from ubc9 to the sumo-1 target Sp100 (Pichler et 
al.,  2002).  RanBP2  is  a  multidomain  protein  with  interaction  sites  for  proteins  including 
Figure  9.  RING  domain.  A.  The  consensus  sequences  that  define  RING  domains.  B.  Schematic 
representation of the cross-brace zinc ligation found in RING domains. C. Worm representations of the 
Cbl RING domain. A and B are taken from Capili et al. (2004). C is modified from PDB structure 1FBV 
by Zheng et al. (2000). 
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nuclear transport receptors, the GTPase Ran, ubc9, and sumoylated GTPase-activating protein 
RanGAP1 (Pichler et al., 2004) (Figure 7). The sumo E3 activity of the 358-kDa RanBP2 was 
mapped  to  a  33-kDa,  286-residue fragment  termed  BP2ΔFG.  This  fragment  contains  two 
approx.  50-residue  long  internal repeats  (IR1  and  IR2)  separated  by  a  25-residue  middle 
domain (M) (Pichler et al., 2002; Matunis and Pickart, 2005) (Figure 8B).    The IR1 is an 
ubiquitin-like protein binding domain. It mediates attachment of both sumo-1 and sumo-2 to 
their substrates (Tatham et al., 2005). It is interesting that IR2 is highly homologous to IR1, 
but it does not bind to ubc9. IR2 can mediate sumo-1, but not sumo-2 attachment. Thus, it is 
supposed to act in a somo-1 specific manner mediated by direct interaction between sumo-1 
and  IR2  motif  (Tatham  et  al.,  2005).  The  M  motif  strongly  enhances  both  IR1  and  IR2 
activity, but does not contain any catalytic activity itself (Pichler et al., 2004). In the sumo-1-
RanGAP1(432-587)-ubc9-RanBP2(IR1)  complex,  the  IR1  domain  of  RanBP2  adopts  an 
extended structure. It binds the β-sheet of ubc9 with its C-terminal fragment that forms an α-
helix. The middle free loop of IR1 extends across ubc9 α1 (Figure 7D). Unlike Pias proteins, 
which interact with the substrate through their C-terminal domains, no direct connection has 
been found between RanBP2 and any of its substrates found up to now (discussed below). 
Thus, it is proposed that RanBP2 acts as an E3 by binding both sumo and ubc9 to position the 
sumo-E2-thioester in an optimal orientation, thereby enhancing conjugation (Reverter and 
Lima, 2005). 
Pc2 
Pc2 was identified as a sumo E3 for the transcriptional corepressors CtBP (C-terminal binding 
protein of adenovirus E1A) and CtBP2, both in vivo and in vitro (Kagey et al., 2003; Lin et al., 
2003).  It  is  a  member  of  the  polycomb  group of  proteins,  which  were  first  identified  in 
Drosophila as regulators of segment identity (Simon et al., 1992; Simon and Tamkun, 2002). 
Human Pc2 shares only limited sequence similarity to Drosophila Pc, primarily in the amino-
terminal chromodomain and a small region at the extreme carboxyl-terminus (Satijn et al., 
1997). Pc2 has no obvious sequence similarity to other known E3, suggesting that it is a new 
group of sumo E3, with no apparent unifying structural features. However, the enhancement 
of CtBP sumoylation by Pc2 in vitro is very modest, and Pias1, Piasx, and RanBP2 can also 
promote CtBP sumoylation, suggesting that there may be multiple factors involved in CtBP 
sumoylation  (Kagey  et  al.,  2003;  Johnson,  2004). In  mammalian  cells,  various  polycomb 
proteins, including Pc2, have a distinct subnuclear localization, forming discrete foci, termed 
polycomb bodies (Gerasimova and Corces, 1998). A CTD fragment of Pc2 (Figure 8C, amino  
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acids 401–558) interacts with both ubc9 and CtBP, and recruits both proteins to polycomb 
bodies. An E3 activity has been shown, not in the CTD in vivo, but a separate domain in the 
NTD, which has E3 activity on its own in vitro. In vivo, both the NTD and the CTD domains 
contribute to E3 activity (Kagey et al., 2005).   
SUMOYLATION COMPLEX 
The  processes  of  ubiquitination,  sumoylation  and  neddylation  are  quite  similar,  thus  they 
probably  share  a  common  mechanism.  With  the  available  structures  of  proteins  and 
complexes involved in different modification pathways, we here propose how and in which 
sequence the sumoylation machinery is assembled. 
Sumoylation model 
Figure 10 depicts all structures of the protein components of the sumoylation pathway. They 
are IR1 domain of RanBP2 (Figure 10A), ubc9 (Figure 10B), a cartoon of Pias1 bound with 
STAT1 (Figure 10C), sumo-1 in free, adenylated and activated states (Figure 10D), and the 
aos1/uba2 complex (Figure 10E).   
Aos1-uba2 and ubc9 form a complex and serve as the core components of the machinery. 
Ubc9 resides in the upper part of the E1 cleft 1, with firm contact with the UbL domain of E1 
as  illustrated  in  Figure  11.  It  is  not  known  whether  there  are  any  other  interactions  to 
strengthen the location of ubc9. Its catalytic site Cys93 should be near to Cys173 of uba2 
(Huang et al., 2005). As discussed below, it is likely that RanBP2 is also a member of the 
core  machinery.  The  C-terminus  of  RanBP2  IR1  domain  binds  to  Ubc9;  the  N-terminus 
extends, crosses the E1 UbL domain, and extends to E1 cleft 1. It is also shown in the sumo-
ubc9-RanBP2-RanGAP1 that the M domain, which follows C-terminal IR1, turns back and 
extends to the same direction as N-terminal IR1. Although not shown in the crystal structure 
of the complex, it can be imagined that the IR2 domain of RanBP2 also resides over E1 cleft 
2, even extends further than IR1. Thus, it is speculated that IR2 domain plays some roles in 
recruiting  the  sumo  molecule  to  the  nucleotide-binding  site  and  translocating  to  the  E1 
catalytic Cys site afterwards. One ATP molecule is bound in a pocket around the Gly-x-Gly-
x-x-Gly nucleotide binding motif (Walden et al., 2003b), which is conserved among ubiquitin, 
sumo  and  Nedd8  activating  enzymes.  Of  ubc9,  the  binding  sites  for  Pias  protein  RING 
domain and for some substrates such as RanGAP1 are exposed. 
For a sumoylation reaction, a sumo molecule is bound to the adenylation center. Contacts 
between the C-terminal carboxylate of sumo-1 Gly97 and the ATP α-phosphate place the C- 
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terminal sumo-1 glycine in an optimal orientation for attack at the ATP α-phosphate (Lois 
and Lima, 2005). Next, a thioester band forms between E1 catalytic Cys173 and sumo. As the   
Cys173 is far from the adenylation domain, sumo-1 needs to translocate and probably make 
an 180
o turn in order to get into the right position to form the thioester bond with E1, and later 
on with E2. This force may originate from M and/or IR2 domain of RanBP2 that are supposed 
to be in vicinity, or pushed by a new free sumo-1 that comes and binds with the ATP in the 
nucleotide binding motif. As the M-IR2 fragment of RanBP2, which contains both M and IR2 
domains (Figure 8B), has been shown to interact with sumo-1 in GST pulldown assays in a 
ubc9 independent way (Tatham et al., 2005), thus make it possible that the M-IR2 fragments 
Figure 10. Components of the sumoylation machinery. A. RanBP2-IR1 (2,631-2,693). B. Ubc9 (2-157). C. 
PIAS protein loaded with a substrate STAT1. D. Sumo-1 (20-97). E. E1 complex aos1-uba2. 
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play a role in recruiting and translocation sumo. The activated sumo is then transferred to E2 
and later to the substrate through interactions between E1-E2 and E2-substrate, respectively.   
 
After conjugation with a sumo molecule, the E2 protein makes a translocation, with the E1 
UbL domain, along the rotation of the linkage between the UbL domain and the rest of the E1 
protein (Huang et al., 2005. Figure 11). Thus the catalytic Cys sites of E1 and E2 proteins are 
Figure 11. A. Proposed sequence of assembly of the sumoylation complex. B. Blow-up of the box in A. 
1.  One sumo enters into adenylation areas and is adenylated. 
2.  A second sumo enters into the adenylation areas and shifts the first somo to E1 catalytic Cys173. 
During translocation, the first sumo undergoes a turn of 180
o, and reaches the correct position to bind 
E2 and/or RanBP2.   
3.  Sumo is transferred to E2 catalytic site Cys93.   
4.  E2, together with UbL domain of E1, turn along UbL axis. Thus E2 and E3 catalytic sites detach. 
5.  A Pias protein bound with a substrate binds to E2. RanGAP1 binds E2 by itsself. Both E2 and the 
substrate are ready to accept sumo. 
6.  Sumo is further transferred to the substrate. 
7.  The sumoylated substrate exits the complex. 
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detached. E1 catalytic site again is available for another sumo conjugation. A substrate is 
recruited to the E2 by an E3 ligase, and is conjugated with the sumo. At last, the sumoylated 
substrate leaves the Pias protein and departs from the complex. The SIM of Pias protein may 
play  a  role  for  the  dissociation  of  sumoylated  substrate  and  Pias.  Free  Pias  protein  then 
associates with another unmodified substrate and is ready for another round of sumoylation. 
 
Prospective of the Model 
In  the  previous  section,  a  model  of  the  sumoylation  complex  was  described  under  the 
assumption that aos1/uba2-ubc9-RanBP2 forms the core of the sumoylation machinery. Both 
RanBP2 and Pias proteins are needed for an efficient modification: RanBP2 is a component in 
the  core  machinery  for  all  sumoylation  reaction,  and  Pias  proteins  work  as  adaptors  for 
recruiting substrates to the core. Of the three types of E3 ligases found so far, only Pc2 is not 
involved in the model. The only found Pc2 substrates for sumoylation are CtBP proteins, 
whose sumoylation was also enhanced by Pias proteins and RanBP2 (Kagey et al., 2003). The 
studies on Pc2 function were performed in cells (Kagey et al., 2003; Kagey et al., 2005), thus 
one cannot exclude the involvement of other cellular proteins in the sumoylation of CtBPs. 
About 100 proteins have been found to be sumoylation substrates. Most of them were initially 
identified as interactors for Pias proteins and/or ubc9 by protein-protein interaction assays, 
such as yeast two-hybrid and/or GST pulldown, and confirmed later to be sumoylated by 
sumoylation  and/or  mutagenesis  assays.  For  only  four  proteins,  the  sumoylation  reactions 
have not been reported to be enhanced by Pias proteins. These are RanGAP1 (Matunis et al., 
1996; Mahajan et al., 1997), Sp100 (Pichler et al., 2002), promyelocytic leukaemia protein 
(PML) (Tatham et al., 2005) and histone deacetylase 4 (HDAC4) (Kirsh et al., 2002). All 
these proteins were initially found to be endogenously sumoylated in cell extracts, which is an 
unusual observation as most sumoylated proteins are quickly desumoylated before analysis. 
For references, see Matunis et al., 1996; Mahajan et al., 1997; Sternsdorf et al., 1997; Kirsh 
et al., 2002. Actually, RanBP2 does not directly interact with either RanGAP1 or Sp100 in 
pulldown assays (Matunis et al., 1998; Pichler et al., 2002), and no direct interaction between 
RanBP2 and the other two substrates has been shown either.   
As RanBP2 is located in the core of the sumoylation complex and thus does not interact with 
these four substrates, there must be some other interactions to recruit these substrates to the 
core. RanGAP1 has a second binding site for E2 (Pichler et al., 2004), which may help in the 
reaction. PML contains a RING domain (Borden et al., 1995), which may mediate direct  
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interactions between PML and ubc9. Once proven, it may be further deduced that PML may 
also work as an adaptor between ubc9 and other proteins in the PML-nuclear body, such as 
Sp100.  Sp100  and  HDAC1/4/6  have  been  shown  to  be  sumoylated  in  vitro,  and  these 
sumoylations were enhanced by addition of RanBP2. But as these assays were performed 
with  HeLa  cell  extracts  (Kirsh  et  al.,  2002;  Pichler  et  al.,  2002),  there  may  have  been 
additional factors in the cell extracts that aided in this reaction. Actually, HDAC6 has a RING 
domain, and it may work as an adaptor for other HDAC proteins. It has been shown that 
nuclear localization is a prerequisite for HDAC4 sumoylation (Kirsh et al., 2002).   
According to the model, RanBP2 and Pias proteins enhance the recruitment of sumo and 
substrates, respectively, to the core. It suggests that both of them may be able to enhance 
sumoylation. Actually, it has been shown that both RanBP2 and some Pias proteins enhance 
sumoylation of the transcription corepressor CtBP (Lin et al., 2003) and Mdm2 (Miyauchi et 
al.,  2002)  in  in vitro  sumoylation  assays.  In  addition,  the  model  also  suggests  that  both 
RanBP2 and Pias proteins are needed for sumoylation. Of the numerous sumoylation assays, 
those performed in vivo, or in vitro but with cell extracts, can be considered to contain both 
RanBP2 and Pias proteins, or their homologues. The in vitro sumoylation assays with purified 
proteins are supposed to lack other protein contaminations. But obviously in vitro assays do 
not faithfully reproduce the physiological substrate selection mechanisms (Johnson, 2004). 
The  intracellular  space  provides  a  highly  compartmentalized  system  for  sumoylation 
pathways (Gunning et al., 1998). In cells, E3 adaptors are needed to recruit the substrates to 
the core. But in the in vitro sumoylation system, as the reaction is performed in solution, 
different protein molecules will meet randomly with high frequency. That may be the reason 
for altered sumoylation levels observed without RanBP2 or Pias proteins in most in vitro 
sumoylation assays. It is interesting that in the functional assays of Pias proteins (without 
addition of RanBP2), the ratio of sumo: E1: E2: substrate was approximately 50: 1: 1: 8 
(Kahyo et al., 2001; Kirsh et al., 2002), so sumo was 50-fold excess over E1-E2. Conversely, 
in the assay for RanBP2 (without addition of Pias proteins), the ratio of sumo: E1: E2 was 5: 
1: 1 (Pichler et al., 2002). This difference suggests that high levels of sumo and substrates can 
compensate for deficiencies caused by the lack of RanBP2 and E3 adaptors, respectively.   
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